• Exploring the role of a multidisciplinary hereditary gynecologic oncology clinic in epithelial ovarian cancer risk-reducing surgical decision-making practices: A mixed-methods study.
    • Casalino S, Bruce S, Serfas K, Altman AD, Kean S, Lambert P, McManus KJ, Hartley JN, Nachtigal MW.
    • J Genet Couns. 2023 Feb 20. doi: 10.1002/jgc4.1684. Epub ahead of print.
    • The Psychosocial Impact of the Decision to Undergo Risk-Reducing Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication.
    • Alves-Nogueira AC, Melo D, Carona C, Figueiredo-Dias M.
    • Curr Oncol. 2023 Feb 18;30(2):2429-2440. doi: 10.3390/curroncol30020185.
    • Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.
    • Leblanc E, Narducci F, Ferron G, Mailliez A, Charvolin JY, El Hajj H, Guyon F, Fourchotte V, Lambaudie E, Crouzet A, Fouche Y, Gouy S, Collinet P, Caquant F, Pomel C, Golfier F, Vaini-Cowen V, Fournier I, Salzet M, Tresch E, Probst A, Lemaire AS, Le Deley MC, Hudry D.
    • Cancers (Basel). 2023 Feb 10;15(4):1141. doi: 10.3390/cancers15041141.

    •• Identifier: NCT01608074: Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy). (ClinicalTrials.gov . Accessed 2023 Feb 12.)

    • Counselling of path_BRCA carriers who are considering risk-reducing oophorectomy.
    • Manley K, Ryan N, Jenner A, Newton C, Hillard T.
    • Post Reprod Health. 2023 Feb 9:20533691231156640. doi: 10.1177/20533691231156640. Epub ahead of print.
    • Review
    • Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic.
    • Zimovjanova M, Bielcikova Z, Miskovicova M, Vocka M, Zimovjanova A, Marian Rybar M, Novotny J, Petruzelka L.
    • Cancers (Basel). 2023 Feb 8;15(4):1072. doi: 10.3390/cancers15041072.
    • Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
    • Terra L, Lee Meeuw Kjoe PR, Agelink Van Rentergem JA, Beekman MJ, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Mourits MJE, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Van Der Wall E, Van Leeuwen FE, Schagen SB.
    • BJOG. 2023 Jan 30. doi: 10.1111/1471-0528.17415. Epub ahead of print.
    • A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany.
    • van der Ven J, Linz VC, Anic K, Schmidt MW, Loewe A, Krajnak S, Schmidt M, Kommoss S, Schmalfeldt B, Sehouli J, Hasenburg A, Battista MJ.
    • Arch Gynecol Obstet. 2023 Jan 27. doi: 10.1007/s00404-023-06919-8. Epub ahead of print.
    • Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review.
    • Nitschke AS, Abreu do Valle H, Dawson L, Kwon JS, Hanley GE.
    • Cancers (Basel). 2023 Jan 24;15(3):711. doi: 10.3390/cancers15030711.
    • Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan.
    • Nomura H, Abe A, Fusegi A, Yoshimitsu T, Misaka S, Murakami A, Matsumoto T, Tsumura S, Kanno M, Aoki Y, Netsu S, Omi M, Tanigawa T, Okamoto S, Omatsu K, Yunokawa M, Kanao H, Habano E, Arakawa H, Kaneko K, Ueki A, Haruyama Y, Inari H, Ueno T.
    • Sci Rep. 2023 Jan 19;13(1):1018. doi: 10.1038/s41598-023-28304-w.
    • Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Chiariello G, Lepera A, Cazzato G, Cascardi E, Damiani GR, Cicinelli E, Cormio G.
    • Hormones (Athens). 2023 Jan 13. doi: 10.1007/s42000-022-00427-1. Epub ahead of print.
    • Review
    • The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, Pinto V, Silvestris E, Kardhashi A, Cicinelli E, Cascardi E, Cormio G.
    • Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764.
    • Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    • Maksimenko J, Rodrigues PP, Nakazawa-Miklaševiča M, Pinto D, Miklaševičs E, Trofimovičs G, Gardovskis J, Cardoso F, Cardoso MJ.
    • JMIR Form Res. 2022 Dec 29;6(12):e37144. doi: 10.2196/37144.
    • The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    • Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, Foulkes WD, Neuhausen SL, Senter L, Moller P, Bordeleau L, Fruscio R, Velsher L, Zakalik D, Olopade OI, Eng C, Pal T, Cullinane CA, Couch FJ, Kotsopoulos J, Sun P, Lubinski J, Narod SA.
    • Cancer. 2022 Dec 26. doi: 10.1002/cncr.34615. Epub ahead of print.
    • Risk-Reducing Salpingo-Oophorectomy (RRSO) Combined with Simultaneous Mastectomy in Women with BRCA 1-2 Mutation Carriers: The Surgical Technique, the Feasibility and Patients' Satisfaction of Multiple Surgeries.
    • Saccardi C, Spagnol G, Saibene T, De Lorenzo LS, Marchetti M, Bonaldo G, Michieletto S, Toffanin MC, Noventa M, Tozzi R.
    • J Clin Med. 2022 Dec 18;11(24):7502. doi: 10.3390/jcm11247502.
    • Hysterectomy by transvaginal natural orifice transluminal endoscopic surgery: An Italian initial experience.
    • Interdonato ML, Scollo P, Bignardi T, Massimello F, Ferrara M, Donatiello G, Caretto M, Mannella P, Pecorino B, Meroni MG, Simoncini T.
    • Front Med (Lausanne). 2022 Dec 13;9:1018232. doi: 10.3389/fmed.2022.1018232.
    • Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
    • Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L, Legood R, Manchanda R.
    • Cancers (Basel). 2022 Dec 12;14(24):6117. doi: 10.3390/cancers14246117.
    • Providers' perspectives on the reproductive decision-making of BRCA-positive women.
    • Dason ES, Drost L, Greenblatt EM, Scheer AS, Han J, Sobel M, Allen L, Jacobson M, Doshi T, Wolff E, McMahon E, Jones CA.
    • BMC Womens Health. 2022 Dec 8;22(1):506. doi: 10.1186/s12905-022-02093-2.
    • Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
    • Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
    • Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.
    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
    • Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
    • Terra L, Beekman MJ, Engelhardt EG, Heemskerk-Gerritsen BAM, Van Beurden M, Roeters Van Lennep JE, Van Doorn HC, De Hullu JA, Van Dorst EBL, Mom CH, Slangen BFM, Gaarenstroom KN, van der Kolk LE, Margriet Collée J, Wevers MR, Ausems MGEM, Van Engelen K, Van De Beek I, Berger LPV, Van Asperen CJ, Gomez Garcia EB, Maas AHEM, Hooning MJ, Aaronson NK, Mourits MJE, Van Leeuwen FE.
    • Am J Obstet Gynecol. 2022 Nov 17:S0002-9378(22)02177-9. doi: 10.1016/j.ajog.2022.11.1289. Epub ahead of print.

    •• Identifier: NCT03835793: Health After eaRly Menopause Due to Oophorectomy (HARMOny). (ClinicalTrials.gov . Accessed 2022 Nov 17.)

    • Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
    • Zhang J, Liu M.
    • J Clin Oncol. 2022 Nov 10;40(32):3783. doi: 10.1200/JCO.22.00726. Epub 2022 Jul 12.

    •• Original research:

    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.

    •• Reply, Letter:

    Reply to J. Zhang et al.

    • Reducing the risk of breast cancer.
    • Pederson HJ, Al-Hilli Z, Kurian AW.
    • Cleve Clin J Med. 2022 Nov 1;89(11):643-652. doi: 10.3949/ccjm.89a.21113.
    • The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2.
    • Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A, Rosenthal AN.
    • J Med Genet. 2022 Nov 1:jmedgenet-2022-108741. doi: 10.1136/jmg-2022-108741. Epub ahead of print.
    • Trajectories of metabolic parameters after bilateral oophorectomy in premenopausal women.
    • Kapoor E, Faubion SS, Gazzuola Rocca L, Mielke MM, Smith CY, Rocca WA.
    • Maturitas. 2022 Nov;165:38-46. doi: 10.1016/j.maturitas.2022.07.005. Epub 2022 Jul 21.
    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.
    • Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    • Powell CB, Laurent C, Garcia C, Hoodfar E, Karlea A, Kobelka C, Lee J, Roh J, Kushi LH.
    • Gynecol Oncol. 2022 Oct 8:S0090-8258(22)01857-1. doi: 10.1016/j.ygyno.2022.10.001. Epub ahead of print.
    • What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    • Moss KM, Mishra GD, Krejany EO, Hickey M.
    • Gynecol Oncol. 2022 Oct;167(1):58-64. doi: 10.1016/j.ygyno.2022.07.029. Epub 2022 Aug 4.
    • Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines.
    • Matan LS, Perri T, Kogan L, Brandt B, Meyer R, Levin G.
    • Eur J Obstet Gynecol Reprod Biol. 2022 Nov;278:166-171. doi: 10.1016/j.ejogrb.2022.09.035. Epub 2022 Sep 29.
    • Surgical Menopause and Bilateral Oophorectomy: Effect of Estrogen-Progesterone and Testosterone Replacement Therapy on Psychological Well-being and Sexual Functioning; A Systematic Literature Review.
    • Stuursma A, Lanjouw L, Idema DL, de Bock GH, Mourits MJE.
    • J Sex Med. 2022 Sep 26:S1743-6095(22)01769-6. doi: 10.1016/j.jsxm.2022.08.191. Epub ahead of print.

    Review registration number: CRD42019136698: The effect of hormone replacement therapy on psychological well-being and sexual functioning in women after treatment-induced menopause. (PROSPERO register)

    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • Outcome and management of STIC following opportunistic salpingectomy: systematic review and meta-analysis.
    • Ruel-Laliberté J, Kasasni SM, Oprea D, Viau M.
    • J Obstet Gynaecol Can. 2022 Sep 10:S1701-2163(22)00612-0. doi: 10.1016/j.jogc.2022.08.018. Epub ahead of print.
    • Meta-Analysis
    • Risk-reducing bilateral salpingo-oopherectomy for BRCA mutation carriers via the transvaginal natural orifice transluminal endoscopic surgery approach.
    • Goldenberg M, Revivo PE, Gurevitch S, Mashiach R, Mohr-Sasson A.
    • Int J Gynaecol Obstet. 2022 Sep;158(3):764-765. doi: 10.1002/ijgo.14294. Epub 2022 Jun 16.
    • Scene memory and hippocampal volume in middle-aged women with early hormone loss.
    • Gervais NJ, Gravelsins L, Brown A, Reuben R, Karkaby L, Baker-Sullivan E, Mendoza L, Lauzon C, Almey A, Foulkes WD, Bernardini MQ, Jacobson M, Velsher L, Rajah MN, Olsen RK, Grady C, Einstein G.
    • Neurobiol Aging. 2022 Sep;117:97-106. doi: 10.1016/j.neurobiolaging.2022.05.003. Epub 2022 May 13.
    • A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    • Loizzi V, Cicinelli E, Del Vecchio V, Arezzo F, Deromemaj X, Kardhashi A, Paradiso A, Legge F, Natalicchio MI, Resta L, Resta N, Loconte DC, Cormio G.
    • Acta Biomed. 2022 Aug 31;93(4):e2022051. doi: 10.23750/abm.v93i4.11695.
    • Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.
    • Linz VC, Löwe A, van der Ven J, Hasenburg A, Battista MJ.
    • Front Oncol. 2022 Aug 31;12:951292. doi: 10.3389/fonc.2022.951292.
    • Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy.
    • Trivedi MS, Arber N, Friedman E, Garber JE, Holcomb K, Horowitz NS, Wright JD, Lee JJ, Vornik LA, Abutaseh S, Castile T, Sauter ER, Dimond E, Heckman-Stoddard BM, House M, Samimi G, Brown PH, Crew KD.
    • Cancer Prev Res (Phila). 2022 Aug 24:OF1-OF6. doi: 10.1158/1940-6207.CAPR-22-0051. Epub ahead of print.
    • Commentary

    Identifier: NCT03382574: Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy. (ClinicalTrials.gov)

    • Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
    • Smallwood KG, Crockett S, Huang V, Cullimore V, Davies J, Satti G, Phillips A.
    • J Obstet Gynaecol. 2022 Aug 18:1-7. doi: 10.1080/01443615.2022.2111253. Epub ahead of print.
    • Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.
    • Knerr S, Guo B, Mittendorf KF, Feigelson HS, Gilmore MJ, Jarvik GP, Kauffman TL, Keast E, Lynch FL, Muessig KR, Okuyama S, Veenstra DL, Zepp JM, Goddard KAB, Devine B.
    • Cancer. 2022 Aug 15;128(16):3090-3098. doi: 10.1002/cncr.34349. Epub 2022 Jun 9.
    • Influence of germline test results on surgical decision making in women with invasive breast cancer.
    • Vargason AB, Turner CE, Shriver CD, Ellsworth RE.
    • Cancer Genet. 2022 Aug;266-267:81-85. doi: 10.1016/j.cancergen.2022.07.003. Epub 2022 Jul 13.
    • Surgical management of BRCA-mutation carriers: A single institution experience.
    • Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, Testori A, Errico V, Bianchi P, Biondi E, Torrisi R, Santoro A, Tinterri C.
    • Eur J Surg Oncol. 2022 Aug;48(8):1706-1712. doi: 10.1016/j.ejso.2022.04.024. Epub 2022 Apr 30.
    • Risk-reducing Salpingo-oophorectomy consults and practices during the COVID-19 pandemic.
    • O'Mara AE, Benedict C, Kurian AW, Wagner SK, Diver E.
    • Gynecol Oncol Rep. 2022 Aug;42:101036. doi: 10.1016/j.gore.2022.101036. Epub 2022 Jun 28.
    • Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants.
    • Edaily S, Abdel-Razeq H.
    • Onco Targets Ther. 2022 Jul 27;15:815-826. doi: 10.2147/OTT.S369844.
    • Study: Risk-reducing ovarian cancer surgery and quality of life.
    • [No author given]
    • FORCE. XRAY. 2022 Jul 26.

    Original research:

    Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.

    • Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
    • Marchetti C, Arcieri M, Vertechy L, Ergasti R, Russo G, Zannoni GF, Minucci A, Ercoli A, Scambia G, Fagotti A.
    • Eur J Surg Oncol. 2022 Jul 19:S0748-7983(22)00549-2. doi: 10.1016/j.ejso.2022.07.007. Epub ahead of print.
    • Scar-Free Laparoscopy in BRCA-Mutated Women.
    • Restaino S, Finelli A, Pellecchia G, Biasioli A, Mauro J, Ronsini C, Martina MD, Arcieri M, Della Corte L, Sorrentino F, Driul L, Vizzielli G.
    • Medicina (Kaunas). 2022 Jul 17;58(7):943. doi: 10.3390/medicina58070943.
    • Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal.
    • Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, Foulkes WD, Neuhausen SL, Sun S, Karlan BY, Eisen A, Tung N, Olopade OI, Couch FJ, Huzarski T, Senter L, Bordeleau L, Singer CF, Eng C, Fruscio R, Pal T, Sun P, Narod SA.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1351-1358. doi: 10.1158/1055-9965.EPI-21-1196.
    • Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
    • Mai PL, Miller A, Black A, Falk RT, Boggess JF, Tucker K, Stuckey AR, Rodriguez GC, Wong C, Amatruda TT, Wilkinson KJ, Modesitt SC, Yamada SD, Bixel KL, Glaser GE, Rose PG, Greene MH, Sherman ME.
    • Am J Obstet Gynecol. 2022 Jul;227(1):61.e1-61.e18. doi: 10.1016/j.ajog.2022.02.022. Epub 2022 Feb 22.
    • The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
    • Tomiczek-Szwiec J, Szwiec M, Falco M, Cybulski C, Wokolorczyk D, Jakubowska A, Gronwald J, Stawicka M, Godlewski D, Kilar E, Marczyk E, Siolek M, Wisniowski R, Haus O, Sibilski R, Bodnar L, Sun P, Narod SA, Lubinski J, Huzarski T; Polish Breast Cancer Consortium.
    • Br J Cancer. 2022 Jul;127(1):84-91. doi: 10.1038/s41416-022-01770-1. Epub 2022 Mar 7.
    • Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.
    • Bommer C, Lupatsch J, Bürki N, Schwenkglenks M.
    • Eur J Health Econ. 2022 Jul;23(5):807-821. doi: 10.1007/s10198-021-01396-9. Epub 2021 Nov 12.
    • Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy.
    • Sekine M, Enomoto T, Arai M, Den H, Nomura H, Ikeuchi T, Nakamura S; Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer.
    • J Gynecol Oncol. 2022 Jul;33(4):e46. doi: 10.3802/jgo.2022.33.e46. Epub 2022 Mar 31.
    • Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study.
    • do Valle HA, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE.
    • J Gynecol Oncol. 2022 Jul;33(4):e51. doi: 10.3802/jgo.2022.33.e51. Epub 2022 Mar 30.
    • Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast).
    • Carneiro VCG, Gifoni ACLVC, Mauro Rossi B, Andrade CEMDC, Lima FT, Galvão HCR, Casali da Rocha JC, Silva Barreto LSD, Ashton-Prolla P, Guindalini RSC, Farias TP, Andrade WP, Fernandes PHS, Ribeiro R, Lopes A, Tsunoda AT, Azevedo BRB, Marins CAM, Oliveira Uchôa DNA, Dos Santos EAS, Fernández Coimbra FJ, Dias Filho FA, Lopes FCO, Fernandes FG, Ritt GF, Laporte GA, Guimaraes GC, Feitosa E Castro Neto H, Dos Santos JC, de Carvalho Vilela JB, Meinhardt Junior JG, Cunha JRD, Medeiros Milhomem L, da Silva LM, Maciel LF, Ramalho NM, Leite Nunes R, Guido de Araújo R, de Assunção Ehrhardt R, Delgado Bocanegra RE, Silva Junior TC, Oliveira VR, Silva Surimã W, de Melo Melquiades M, Ribeiro HSC, Oliveira AF.
    • J Surg Oncol. 2022 Jul;126(1):10-19. doi: 10.1002/jso.26812.
    • Guideline
    • Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast).
    • Carneiro VCG, Gifoni ACLVC, Mauro Rossi B, Andrade CEMDC, Lima FT, Galvão HCR, Casali da Rocha JC, Silva Barreto LSD, Ashton-Prolla P, Guindalini RSC, Farias TP, Andrade WP, Fernandes PHS, Ribeiro R, Lopes A, Tsunoda AT, Azevedo BRB, Marins CAM, Oliveira Uchôa DNA, Dos Santos EAS, Fernández Coimbra FJ, Dias Filho FA, Lopes FCO, Fernandes FG, Ritt GF, Laporte GA, Guimaraes GC, Feitosa E Castro Neto H, Dos Santos JC, de Carvalho Vilela JB, Meinhardt Junior JG, Cunha JRD, Medeiros Milhomem L, da Silva LM, Maciel LF, Ramalho NM, Leite Nunes R, Guido de Araújo R, de Assunção Ehrhardt R, Delgado Bocanegra RE, Silva Junior TC, Oliveira VR, Silva Surimã W, de Melo Melquiades M, Ribeiro HSC, Oliveira AF.
    • J Surg Oncol. 2022 Jul;126(1):10-19. doi: 10.1002/jso.26812.
    • Guideline
    • Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.
    • Adolph L, Warias A, Stairs J, Collins-McNeil K, Penney L, Kieser K.
    • BMC Womens Health. 2022 Jun 29;22(1):263. doi: 10.1186/s12905-022-01844-5.
    • Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    • Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, Swisher EM, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, IntHout J, de Hullu JA.
    • J Clin Oncol. 2022 Jun 10;40(17):1879-1891. doi: 10.1200/JCO.21.02016. Epub 2022 Mar 18.
    • Meta-Analysis

    •• Commentary:

    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?

    •• Letter, Commentary:

    Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.

    •• Reply, Letter:

    Reply to J. Zhang et al.

    • Needleoscopic-assisted risk-reducing bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers: Peri-operative outcomes and psychological impact.
    • Rosati A, Fedele C, Fagotti A, Lafuenti L, Gioè A, Chieffo DPR, Vizzielli G, D'Ippolito G, Salutari V, Paris I, Marchetti C, Scambia G, Gueli Alletti S.
    • Eur J Obstet Gynecol Reprod Biol. 2022 Jun;273:1-6. doi: 10.1016/j.ejogrb.2022.03.040. Epub 2022 Mar 30.
    • Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Wang Y, Song Z, Zhang S, Wang X, Li P.
    • Eur J Surg Oncol. 2022 Jun;48(6):1209-1216. doi: 10.1016/j.ejso.2022.02.019. Epub 2022 Feb 18.
    • Meta-Analysis
    • Prophylactic Salpingo-Opphorectomy in Patients With Hereditary Predisposition Genes for Ovarian Cancer.
    • Garrett AA, Mahdi H.
    • JCO Oncol Pract. 2022 Jun;18(6):e846-e848. doi: 10.1200/OP.22.00069. Epub 2022 Mar 8.

    Original research:

    Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.

    • Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy.
    • van Winden LJ, Vermeulen RFM, van den Noort V, Gaarenstroom KN, Kenter GG, Brood-van Zanten MMA, Korse CM, van Beurden M, van Rossum HH.
    • J Endocr Soc. 2022 Apr 25 [eCollection 2022 Jun];6(6):bvac069. doi: 10.1210/jendso/bvac069.
    • Endometrial Cancer and BRCA Mutations: A Systematic Review.
    • Gasparri ML, Bellaminutti S, Farooqi AA, Cuccu I, Di Donato V, Papadia A.
    • J Clin Med. 2022 May 31;11(11):3114. doi: 10.3390/jcm11113114.
    • Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey.
    • Chang YJ, Cho S, Joo J, Ryu KH, Lee S, Cho J, Lim MC, Jung SY, Han JH, Lee ES, Kong SY.
    • J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
    • Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study.
    • Barnard ME, Meeks H, Jarboe EA, Albro J, Camp NJ, Doherty JA.
    • J Med Genet. 2022 May 9:jmedgenet-2021-108402. doi: 10.1136/jmedgenet-2021-108402. Epub ahead of print.
    • Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.
    • Lim N, Hickey M, Young GP, Macrae FA, Kelly C.
    • Int J Gynecol Cancer. 2022 May 3;32(5):646-655. doi: 10.1136/ijgc-2021-003132.
    • Combining Breast and Ovarian Operations Increases Complications.
    • Henn D, Barrera JA, Sivaraj D, Lin JQ, Rizk NM, Ma I, Gurtner GC, Lee GK, Nazerali RS.
    • Plast Reconstr Surg. 2022 May 1;149(5):1050-1059. doi: 10.1097/PRS.0000000000008984. Epub 2022 Mar 2.
    • Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    • Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):540-552. doi: 10.1093/jnci/djac004.

    Commentary:

    Oral Contraceptives and BRCA Cancer: A Balancing Act.

    • Fallopian Tube Originating Ovarian Cancer in a 53-Year-Old Postmenopausal Female With Hereditary Breast Cancer (BRCA) Genes: A Case Study.
    • Garrick I, Ahasan H, Jiang M, Musheyev Y, Ftiha F, Levada M.
    • Cureus. 2022 Apr 7;14(4):e23929. doi: 10.7759/cureus.23929.
    • Information needs of women undergoing gynaecological risk reduction surgery: Applying patient-reported findings to improve service delivery.
    • Jennings B, Ramis MA, Kynoch K, Jagasia N.
    • Aust N Z J Obstet Gynaecol. 2022 Apr;62(2):286-293. doi: 10.1111/ajo.13456. Epub 2021 Nov 9.
    • "It was a no-brainer": A qualitative study of factors driving previvors' decision-making when considering risk-reducing salpingectomy with delayed oophorectomy.
    • Gellman C, Ezratty C, Schwarz J, Kolev V, Blank SV.
    • Gynecol Oncol Rep. 2022 Feb 26 [eCollection 2022 Apr];40:100948. doi: 10.1016/j.gore.2022.100948.
    • Recommendations for diagnosing STIC: a systematic review and meta-analysis.
    • Bogaerts JMA, Steenbeek MP, van Bommel MHD, Bulten J, van der Laak JAWM, de Hullu JA, Simons M.
    • Virchows Arch. 2022 Apr;480(4):725-737. doi: 10.1007/s00428-021-03244-w. Epub 2021 Dec 1.
    • Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.
    • Clarfield L, Diamond L, Jacobson M.
    • Curr Oncol. 2022 Mar 21;29(3):2132-2140. doi: 10.3390/curroncol29030172.
    • The first European gynaecological procedure with the new surgical robot Hugo™ RAS. A total hysterectomy and salpingo-oophorectomy in a woman affected by BRCA-1 mutation.
    • Monterossi G, Pedone Anchora L, Gueli Alletti S, Fagotti A, Fanfani F, Scambia G.
    • Facts Views Vis Obgyn. 2022 Mar;14(1):91-94. doi: 10.52054/FVVO.14.1.014.
    • [A Case of Breast Cancer during Pregnancy Treated with Neoadjuvant Chemotherapy during Pregnancy].
    • Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, Noda H, Taguchi K, Nishiyama K, Murakami A, Yamashita M, Kamei Y, Takada Y.
    • Gan To Kagaku Ryoho. 2022 Mar;49(3):289-292. Japanese.
    • Case report. [Article in Japanese]
    • Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.
    • Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, Grisham RN, Long Roche K, Frey MK, Chi DS, Abu-Rustum N, Aghajanian C, Offit K, Stadler ZK.
    • JCO Oncol Pract. 2022 Mar;18(3):201-209. doi: 10.1200/OP.21.00382. Epub 2021 Sep 28.

    Commentary:

    Prophylactic Salpingo-Opphorectomy in Patients With Hereditary Predisposition Genes for Ovarian Cancer.

    • Major clinical research advances in gynecologic cancer in 2021.
    • Park JY, Lee JY, Lee YY, Shim SH, Suh DH, Kim JW.
    • J Gynecol Oncol. 2022 Mar;33(2):e43. doi: 10.3802/jgo.2022.33.e43.
    • Computerized morphometry analysis of epithelial fimbriae nuclear symmetry in BRCA carriers may identify patients at risk for developing ovarian cancer.
    • Amit A, Sabo E, Petruseva A, Stroller L, Reiss A, Klorin G.
    • Microsc Res Tech. 2022 Mar;85(3):892-899. doi: 10.1002/jemt.23958. Epub 2021 Oct 9.
    • Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.
    • Saul H, Gursul D, Cassidy S, Evans G.
    • BMJ. 2022 Feb 15;376:o258. doi: 10.1136/bmj.o258.
    • Research news

    Original research:

    Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.

    • Serous Tubal Intraepithelial Carcinoma in a Risk-reducing Salpingo-oophorectomy Specimen From a RAD51D Mutation Carrier: A Case Report.
    • Gregory-Davis KJ, Walker A, Colello LS, McKinnon W, Everett E, Chang MC.
    • Int J Gynecol Pathol. 2022 Feb 11. doi: 10.1097/PGP.0000000000000857. Epub ahead of print.
    • Case report
    • Chris Evert's ovarian cancer diagnosis highlights the importance of genetic counseling and testing.
    • [No author given]
    • FORCE. XRAY. 2022 Feb 8.

    Press: Chris Evert opens up about her stage 1C ovarian cancer diagnosis. (ESPN)

    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer.
    • Philp L, Alimena S, Ferris W, Saini A, Bregar AJ, Del Carmen MG, Eisenhauer EL, Growdon WB, Goodman A, Dorney K, Mazina V, Sisodia RC.
    • Gynecol Oncol. 2022 Feb;164(2):421-427. doi: 10.1016/j.ygyno.2021.12.017. Epub 2021 Dec 23.
    • Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.
    • Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, Harvey J, Highton L, Murphy J, Holland C, Edmondson R, Clayton R, Barr L, Harkness EF, Howell A, Lalloo F, Evans DG.
    • J Med Genet. 2022 Feb;59(2):133-140. doi: 10.1136/jmedgenet-2020-107356. Epub 2021 Feb 10.

    Research news:

    Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.

    • Chris Evert opens up about her stage 1C ovarian cancer diagnosis.
    • McKendry C, Evert C.
    • ESPN. 2022 Jan 14.

    News: Chris Evert's ovarian cancer diagnosis highlights the importance of genetic counseling and testing. (FORCE. XRAY.)

    • Special Issue “Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer”.
    • Manchanda R.
    • Cancers (Basel). 2022 Jan 10;14(2):319. doi: 10.3390/cancers14020319.
    • Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
    • Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.
    • Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.
    • Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    • Manchanda R, Gaba F, Talaulikar V, Pundir J, Gessler S, Davies M, Menon U; Royal College of Obstetricians and Gynaecologists.
    • BJOG. 2022 Jan;129(1):e16-e34. doi: 10.1111/1471-0528.16896. Epub 2021 Oct 20.
    • Genetic testing in Non-Hispanic Black women with breast cancer treated within an equal-access healthcare system.
    • Vargason AB, Turner CE, Shriver CD, Ellsworth RE.
    • Genet Med. 2022 Jan;24(1):232-237. doi: 10.1016/j.gim.2021.08.002. Epub 2021 Nov 30.

    Podcast: January 2022: Providing access to quality healthcare for Non-Hispanic Black women reduces mortality. (Genetics in Medicine. GenePod)

    • Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study.
    • Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.
    • Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.
    • Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.
    • Moukadem HA, Al Masry A, Atwani RW, Kreidieh F, Khalil LE, Saroufim R, Daouk S, Dalle IA, El Saghir NS.
    • Eur J Breast Health. 2021 Dec 30;18(1):16-20. doi: 10.4274/ejbh.galenos.2021.2021-5-1.
    • Body Image in BRCA-Positive Young Women Following Bilateral Risk-Reducing Mastectomy: A Review of the Literature.
    • Torrisi C.
    • Front Psychol. 2021 Dec 16;12:778484. doi: 10.3389/fpsyg.2021.778484.
    • Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
    • Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3.
    • Eur J Med Genet. 2021 Dec;64(12):104350. doi: 10.1016/j.ejmg.2021.104350. Epub 2021 Oct 1.
    • Review
    • Bilateral Risk-Reducing Prophylactic Mastectomies in an Unaffected BRCA1 Carrier Using Dermal Sling and Implant.
    • Gupta S, Kadayaprath G, Gupta N, Barthwal V.
    • Indian J Surg Oncol. 2021 Dec;12(Suppl 2):355-358. doi: 10.1007/s13193-021-01370-0. Epub 2021 Jun 16.
    • Case report
    • Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study.
    • Lim H, Kim SI, Hyun S, Lee GB, Seol A, Lee M.
    • Yonsei Med J. 2021 Dec;62(12):1090-1097. doi: 10.3349/ymj.2021.62.12.1090.
    • Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment.
    • Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM.
    • JAMA Netw Open. 2021 Nov 1;4(11):e2131448. doi: 10.1001/jamanetworkopen.2021.31448.

    Commentary:

    Long-term Risk of Cognitive Impairment and Dementia Following Bilateral Oophorectomy in Premenopausal Women-Time to Rethink Policies?

    • Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1/2 mutations.
    • Smith MJ, Gerber D, Olsen A, Khouri OR, Wang Y, Liu M, Smith J, Pothuri B.
    • Am J Obstet Gynecol. 2021 Nov;225(5):508.e1-508.e10. doi: 10.1016/j.ajog.2021.06.070. Epub 2021 Jun 23.
    • Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    • Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.
    • Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.
    • Study Seeks to Prevent Cancer and Extend Quality of Life for Women at Increased Genetic Risk of Ovarian Cancer.
    • Jenks S.
    • FORCE. Blog. 2021 Oct 12.
    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Oct;163(1):148-154. doi: 10.1016/j.ygyno.2021.07.029. Epub 2021 Jul 24.
    • Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline.
    • Jacobson M, Coakley N, Bernardini M, Branco KA, Elit L, Ferguson S, Kim R.
    • Hered Cancer Clin Pract. 2021 Sep 26;19(1):39. doi: 10.1186/s13053-021-00196-9.
    • Vaginal NOTES approach for risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A video demonstration.
    • Netter A, Niddam R, Agostini A, Crochet P.
    • J Gynecol Obstet Hum Reprod. 2021 Sep 2;50(10):102212. doi: 10.1016/j.jogoh.2021.102212. Epub ahead of print.
    • Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome.
    • Wright JD, Silver ER, Tan SX, Hur C, Kastrinos F.
    • JAMA Netw Open. 2021 Sep 1;4(9):e2123616. doi: 10.1001/jamanetworkopen.2021.23616.

    Commentary:

    Exploring Gene-Specific Guidelines for Risk Management of Gynecological Cancer in Lynch Syndrome

    • Role of Routine Peritoneal Biopsies During Risk Reducing Salpingo-Oophorectomy (RRSO).
    • Pross T, Karsten MM, Blohmer JU, Speiser D.
    • Geburtshilfe Frauenheilkd. 2021 Sep;81(9):1031-1038. doi: 10.1055/a-1395-7715. Epub 2021 Sep 13.
    • Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study.
    • do Valle HA, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE.
    • Gynecol Oncol. 2021 Sep;162(3):707-714. doi: 10.1016/j.ygyno.2021.06.022. Epub 2021 Jul 1.
    • Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
    • Nomura H, Ikki A, Fusegi A, Omi M, Aoki Y, Netsu S, Tanigawa T, Matoda M, Okamoto S, Omatsu K, Nakajima T, Ueki A, Tonooka A, Kanao H.
    • Int J Clin Oncol. 2021 Aug 28. doi: 10.1007/s10147-021-02020-9. Epub ahead of print.
    • Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
    • Steenbeek MP, van Bommel MHD, Harmsen MG, Hoogerbrugge N, van Doorn HC, Keurentjes JHM, van Beurden M, Zweemer RP, Gaarenstroom KN, Penders CGJ, Brood-van Zanten MMA, Vos MC, Piek JM, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, IntHout J, de Hullu JA, Hermens RPMG.
    • Gynecol Oncol. 2021 Aug 26:S0090-8258(21)01317-2. doi: 10.1016/j.ygyno.2021.08.019. Epub ahead of print.
    • RE: Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    • Nahshon C, Lavie O.
    • J Natl Cancer Inst. 2021 Aug 23:djab154. doi: 10.1093/jnci/djab154. Epub ahead of print.

    Letter, Reply:

    Response to Nahshon and Lavie.

    Original research:

    Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.

    • Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    • Park B, Kim D, Kim J, Lee BY, Yoon J, Kim SW.
    • Cancer Res Treat. 2021 Aug 9. doi: 10.4143/crt.2021.449. Epub ahead of print.
    • The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    • Kershaw V, Hickey I, Wyld L, Jha S.
    • Eur J Obstet Gynecol Reprod Biol. 2021 Aug 8;265:7-17. doi: 10.1016/j.ejogrb.2021.08.001. Epub ahead of print.
    • Review
    • Bilateral salpingo-oophorectomy and breast cancer risk for BRCA1 and BRCA2 mutation carriers: Assessing the evidence.
    • Conduit C, Milne RL, Friedlander ML, Phillips KA.
    • Cancer Prev Res (Phila). 2021 Aug 4:canprevres.0141.2021. doi: 10.1158/1940-6207.CAPR-21-0141. Epub ahead of print.
    • Breast cancer rate after oophorectomy: A Prospective Danish Cohort Study.
    • Koch T, Jørgensen JT, Christensen J, Dehlendorff C, Priskorn L, Simonsen MK, Duun-Henriksen AK, Andersen ZJ, Juul A, Bräuner EV, Hickey M.
    • Int J Cancer. 2021 Aug 1;149(3):585-593. doi: 10.1002/ijc.33563. Epub 2021 Apr 2.
    • Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    • Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.
    • JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.

    Identifier: NCT02321228: Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (TUBA). (ClinicalTrials.gov)

    Research news: Study: Risk-reducing ovarian cancer surgery and quality of life. (FORCE. XRAY.)

    • A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk-reducing surgery for hereditary breast and ovarian cancer.
    • Hirayama T, Inayama Y, Odajima S, Yamanaka A, Sekine M, Terao Y, Koide K, Kuwabara Y, Yahata H, Yanaihara N, Nagase S, Kobayashi Y, Sekizawa A.
    • J Obstet Gynaecol Res. 2021 Aug 1. doi: 10.1111/jog.14952. Epub ahead of print.
    • Conference news
    • What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Domchek SM, Kirk J, Brand A, Trainer A, Mishra GD, Baker FC.
    • Gynecol Oncol. 2021 Aug;162(2):447-453. doi: 10.1016/j.ygyno.2021.05.036. Epub 2021 Jun 8.
    • Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers - an Israeli matched pair study.
    • Perri T, Levin G, Naor-Revel S, Eliassi-Revivo P, Lifshitz D, Friedman E, Korach J.
    • Int J Gynaecol Obstet. 2021 Jul 29. doi: 10.1002/ijgo.13843. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • BRCA, breast cancer and in vitro fertilization: How should we advise our patients?
    • García-Planells J, Francés BS, Diez-Juan A.
    • Fertil Steril. 2021 Jul 8:S0015-0282(21)00505-7. doi: 10.1016/j.fertnstert.2021.06.011. Epub ahead of print.

    Original research:

    Fertility treatments and breast cancer risk in Jewish Israeli BRCA mutation carriers.

    • Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location.
    • Sekine M, Nishino K, Enomoto T.
    • Genes (Basel). 2021 Jul 8;12(7):1050. doi: 10.3390/genes12071050.
    • A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.
    • Briollais L.
    • Stat Methods Med Res. 2021 Jul 7:9622802211008945. doi: 10.1177/09622802211008945. Epub ahead of print.
    • Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed.
    • Conduit C, Milne RL, Phillips KA.
    • JAMA Oncol. 2021 Jul 1. doi: 10.1001/jamaoncol.2021.2037. Epub ahead of print.
    • Letter, Comment

    Letter, Reply:

    Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply.

    Original research:

    Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.

    • What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    • Hickey M, Moss KM, Mishra GD, Krejany EO, Domchek SM, Wark JD, Trainer A, Wild RA.
    • Gynecol Oncol. 2021 Jul;162(1):88-96. doi: 10.1016/j.ygyno.2021.04.038. Epub 2021 May 7.
    • Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    • Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A.
    • Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714. Epub ahead of print.
    • Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation.
    • Badiner N, Nchako CM, Ma L, Frey MK.
    • Gynecol Oncol Rep. 2021 May 25;37:100795. doi: 10.1016/j.gore.2021.100795.
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers.
    • Carneiro VCG, Ramalho NM.
    • Int J Gynecol Cancer. 2021 May 14:ijgc-2021-002682. doi: 10.1136/ijgc-2021-002682. Epub ahead of print.
    • Letter

    Letter, Reply:

    Response to: Should we or should we not? Risk reduction bilateral salpingectomy for BRCA mutation carriers.

    Review:

    Fertility preservation in patients with BRCA mutations or Lynch syndrome.

    • Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.
    • Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, Jung Y, Kim K, Choi YJ.
    • Cancers (Basel). 2021 May 11;13(10):2300. doi: 10.3390/cancers13102300.
    • A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
    • Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER.
    • Gynecol Oncol Rep. 2021 May 5;36:100772. doi: 10.1016/j.gore.2021.100772.
    • Did Breastfeeding my Daughter Reduce my Ovarian Cancer Risk?
    • Haarlander T.
    • FORCE. Blog. 2021 May 3.

    Research news: Study: Breastfeeding may lower risk of ovarian cancer in women with BRCA mutations. (FORCE. XRAY.)

    Original research:

    Hereditary Ovarian Cancer Clinical Study Group. Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.

    • Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article.
    • Sourouni M, Kiesel L.
    • Geburtshilfe Frauenheilkd. 2021 May;81(5):549-554. doi: 10.1055/a-1390-4353. Epub 2021 May 20.
    • What happens after menopause? (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    • Hickey M, Moss KM, Brand A, Wrede CD, Domchek SM, Meiser B, Mishra GD, Joffe H.
    • Gynecol Oncol. 2021 May;161(2):527-534. doi: 10.1016/j.ygyno.2021.02.001. Epub 2021 Feb 11.
    • Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing.
    • Cummings S, Roman SS, Saam J, Bernhisel R, Brown K, Lancaster JM, Usha L.
    • J Ovarian Res. 2021 Apr 29;14(1):61. doi: 10.1186/s13048-021-00809-w.
    • Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • J Cancer Res Clin Oncol. 2021 Apr 22. doi: 10.1007/s00432-021-03629-z. Epub ahead of print.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • Controversies in Hereditary Cancer Management.
    • AlHilli MM, Pederson HJ.
    • Obstet Gynecol. 2021 Apr 8. doi: 10.1097/AOG.0000000000004364. Epub ahead of print.
    • The management of menopausal symptoms in women following treatment for cancer at a specialist menopause service.
    • Chakrabarti R, Holloway D, Bruce D, Rymer J.
    • Post Reprod Health. 2021 Apr 7:20533691211000548. doi: 10.1177/20533691211000548. Epub ahead of print.
    • Why So Many of Us Quit Taking Tamoxifen.
    • Horner K.
    • FORCE. Blog. 2021 Apr 6.

    Research news: Study: How breast cancer patients experience hormone therapy (FORCE. XRAY.)

    • HER2-positive breast cancer in a germline BRCA1 gene large deletion carrier.
    • Uchida N, Takeshita M, Suda T, Matsui Y, Yoshida M.
    • Int Cancer Conf J. 2021 Apr 3;10(3):181-185. doi: 10.1007/s13691-021-00481-3.
    • Case report
    • Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants.
    • Choi YH, Terry MB, Daly MB, MacInnis RJ, Hopper JL, Colonna S, Buys SS, Andrulis IL, John EM, Kurian AW, Briollais L.
    • JAMA Oncol. 2021 Apr 1;7(4):585-592. doi: 10.1001/jamaoncol.2020.7995.

    Letter, Comment:

    Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed.

    Letter, Reply:

    Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants-Caution Needed-Reply.

    • Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    • Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Nakken S, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W, Vangala D, Perne C, Strauß HG, Tecklenburg J, Holinski-Feder E, Steinke-Lange V, Mecklin JP, Plazzer JP, Pineda M, Navarro M, Vidal JB, Kariv R, Rosner G, Piñero TA, Gonzalez ML, Kalfayan P, Ryan N, Ten Broeke SW, Jenkins MA, Sunde L, Bernstein I, Burn J, Greenblatt M, de Vos Tot Nederveen Cappel WH, Della Valle A, Lopez-Koestner F, Alvarez K, Büttner R, Görgens H, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M, Rahner N, Weitz J, Pylvänäinen K, Renkonen-Sinisalo L, Lepistö A, Auranen A, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Therkildsen C, Okkels H, Ketabi Z, Denton OG, Rødland EA, Vasen H, Neffa F, Esperon P, Tjandra D, Möslein G, Sampson JR, Evans DG, Seppälä TT, Møller P.
    • Genet Med. 2021 Apr;23(4):705-712. doi: 10.1038/s41436-020-01029-1. Epub 2020 Dec 1.
    • Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
    • Michaelson-Cohen R, Gabizon-Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, Levy-Lahad E, Paluch-Shimon S.
    • Eur J Cancer. 2021 Mar 16;148:95-102. doi: 10.1016/j.ejca.2021.02.007. Epub ahead of print.
    • A prospective controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy.
    • Islam RM, Davis SR, Bell RJ, Tejada-Berges T, Wrede CD, Domchek SM, Meiser B, Kirk J, Krejany EO, Hickey M.
    • Menopause. 2021 Mar 15;28(7):748-755. doi: 10.1097/GME.0000000000001766.
    • Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    • Cowan R, Nobre SP, Pradhan N, Yasukawa M, Zhou QC, Iasonos A, Soslow RA, Arnold AG, Trottier M, Catchings A, Roche KL, Gardner G, Robson M, Abu Rustum NR, Aghajanian C, Cadoo K.
    • Gynecol Oncol. 2021 Mar 9:S0090-8258(21)00142-6. doi: 10.1016/j.ygyno.2021.02.006. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Forged Genetic Test Report Leads to Incorrect Management.
    • Ray T.
    • Precision Oncology News. Diagnostics. 2021 Mar 1.
    • Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    • Crosbie EJ, Flaum N, Harkness EF, Clayton RD, Holland C, Martin-Hirsch P, Wood N, Keating P, Woodward ER, Lalloo F, Donnai P, Edmondson RJ, Evans DG.
    • Int J Cancer. 2021 Mar 1;148(5):1155-1163. doi: 10.1002/ijc.33378. Epub 2020 Nov 11.
    • The needs of Southeast Asian BRCA mutation carriers considering risk-reducing salpingo-oophorectomy: a qualitative study.
    • Sa'at H, Lee YK, Yoon SY, Wong SW, Woo YL, Barlow-Stewart K, Mohd Taib NA.
    • Fam Cancer. 2021 Feb 19. doi: 10.1007/s10689-021-00232-6. Epub ahead of print.
    • Survival from breast cancer in women with a BRCA2 mutation by treatment.
    • Evans DG, Phillips KA, Milne RL, Fruscio R, Cybulski C, Gronwald J, Lubinski J, Huzarski T, Hyder Z, Forde C, Metcalfe K, Senter L, Weitzel J, Tung N, Zakalik D, Ekholm M, Sun P, Narod SA; kConFab Investigators, Polish Hereditary Breast Cancer Consortium, Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2021 Feb 18. doi: 10.1038/s41416-020-01164-1. Epub ahead of print.
    • Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study.
    • Gaba F, Goyal S, Marks D, Chandrasekaran D, Evans O, Robbani S, Tyson C, Legood R, Saridogan E, McCluggage WG, Hanson H, Singh N, Evans DG, Menon U, Manchanda R; PROTECTOR team.
    • J Med Genet. 2021 Feb 10:jmedgenet-2020-107501. doi: 10.1136/jmedgenet-2020-107501. Epub ahead of print.

    Research news: Ovarian Cancer Prevention: How Patients Decide on Surgery. (Medscape)

    • Association of Premenopausal Bilateral Oophorectomy With Restless Legs Syndrome.
    • Huo N, Smith CY, Gazzuola Rocca L, Rocca WA, Mielke MM.
    • JAMA Netw Open. 2021 Feb 1;4(2):e2036058. doi: 10.1001/jamanetworkopen.2020.36058.
    • Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    • Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.
    • Menopause. 2021 Feb 1. doi: 10.1097/GME.0000000000001737. Epub ahead of print.
    • Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study).
    • Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de Hullu JA, Mom C, van Dorst EBL, Mourits MJE, Slangen BFM, Gaarenstroom KN, Zillikens MC, Leiner T, van der Kolk L, Collee M, Wevers M, Ausems MGEM, van Engelen K, Berger LP, van Asperen CJ, Gomez-Garcia EB, van de Beek I, Rookus MA, Hauptmann M, Bleiker EM, Schagen SB, Aaronson NK, Maas AHEM, van Leeuwen FE.
    • JMIR Res Protoc. 2021 Jan 22;10(1):e24414. doi: 10.2196/24414.

    Study Record Detail: Health After eaRly Menopause Due to Oophorectomy (HARMOny). (ClinicalTrials.gov)

    • Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
    • Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.
    • Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    • Grandi G, Perrone AM, Perrone A, Mandato VD, Comerci G, Sammarini M, Merisio C, Amadori A, Stefanetti M, Martinello R, Facchinetti F, De Iaco P; Brca Emilia-Romagna Gyneco-Oncological (BERGO) Collaborative Group.
    • Maturitas. 2021 Jan;143:59-64. doi: 10.1016/j.maturitas.2020.08.011. Epub 2020 Aug 31.
    • Factors associated with the decision to undergo risk-reducing salpingo-oophorectomy among women at high risk for hereditary breast and ovarian cancer: a systematic review.
    • Park SY, Kim Y, Kim S.
    • Korean J Women Health Nurs. 2020 Dec 31;26(4):285-299. doi: 10.4069/kjwhn.2020.11.19. Epub 2020 Dec 9.
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Study: Women support delayed removal of ovaries.
    • [No author given]
    • FORCE. XRAY. 2020 Dec 24.

    Original research:

    Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

    • The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
    • Hickey I, Jha S, Wyld L.
    • Gynecol Oncol. 2020 Dec 11:S0090-8258(20)34164-0. doi: 10.1016/j.ygyno.2020.12.001. Epub ahead of print.
    • Review
    • Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis.
    • Nahshon C, Segev Y, Gemer O, Bar Noy T, Schmidt M, Ostrovsky L, Lavie O.
    • Gynecol Oncol. 2020 Dec 9:S0090-8258(20)34162-7. doi: 10.1016/j.ygyno.2020.11.034. Epub ahead of print.
    • Review
    • Can personality traits affect the quality of life of women with the BRCA1/BRCA2 mutations before and after prophylactic adnexectomy?
    • Stanisz M, Schneider-Matyka D, Panczyk M, Branecka-Wozniak D, Kurzawa R, Knyszynska A, Grochans E.
    • Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12342-12349. doi: 10.26355/eurrev_202012_24028.
    • Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study.
    • Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S.
    • Cancers (Basel). 2020 Nov 27;12(12):3543. doi: 10.3390/cancers12123543.
    • Endometrial cancer in germline BRCA mutation carriers: a systematic review and meta-analysis.
    • Matanes E, Volodarsky-Perel A, Eisenberg N, Rottenstreich M, Yasmeen A, Mitric C, Lau S, Salvador S, Gotlieb WH, Kogan L.
    • J Minim Invasive Gynecol. 2020 Nov 26:S1553-4650(20)31141-9. doi: 10.1016/j.jmig.2020.11.023. Epub ahead of print.
    • Review
    • Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.
    • Lu G, Lu T, Pan J, Guo L, Pang Y, Liu P.
    • Arch Gynecol Obstet. 2020 Nov 20. doi: 10.1007/s00404-020-05887-7.
    • Review
    • No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
    • van Bommel MHD, de Jong MA, Steenbeek MP, Bots ML, van Westerop LLM, Hopman MTE, Hoogerbrugge N, de Hullu JA, Maas AHEM.
    • J Cardiol. 2020 Nov 20:S0914-5087(20)30364-6. doi: 10.1016/j.jjcc.2020.11.005. Epub ahead of print.
    • Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective.
    • [No author given]
    • Clinical OMICs. Molecular Dx. 2020 Nov 17.

    Original research:

    Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.

    • Concurrent Prophylactic Mastectomy, Immediate Reconstruction, and Salpingo-Oophorectomy in High-Risk Patients: A Case Series.
    • D'Abbondanza JA, George R, Kives S, Musgrave MA.
    • Plast Surg (Oakv). 2020 Nov;28(4):243-248. doi: 10.1177/2292550320928551. Epub 2020 Jun 4.
    • Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations.
    • Pouptsis A, Swafe L, Patwardhan M, Stavraka C.
    • Front Oncol. 2020 Oct 20;10:553080. doi: 10.3389/fonc.2020.553080. PMID: 33194613; PMCID: PMC7607003.
    • Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest.
    • Worcester S.
    • Medscape. News & Perspective. 2020 Oct 16.

    Original research:

    Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.

    • Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
    • Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.
    • Jpn J Clin Oncol. 2020 Oct 10:hyaa173. doi: 10.1093/jjco/hyaa173. Epub ahead of print.
    • BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.
    • Lynce F, Schlam I, Geng X, Peshkin BN, Friedman S, Dutil J, Nahleh Z, Campos C, Ricker C, Rodriguez P, Denduluri N, Ahn J, Isaacs C, Graves KD.
    • J Genet Couns. 2020 Oct 3. doi: 10.1002/jgc4.1322. Epub ahead of print.
    • Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    • Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, Hassen D, Snyder SR, Graves JA, Peterson JF, Williams MS, Veenstra DL.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2022874. doi: 10.1001/jamanetworkopen.2020.22874.

    Press: Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective. (Clinical OMICs)

    • Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
    • Trister R, Jacobson M, Nguyen P, Sobel M, Allen L, Narod SA, Kotsopoulos J.
    • Fam Cancer. 2020 Sep 23. doi: 10.1007/s10689-020-00208-y. Epub ahead of print.
    • Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    • Carr CE, Chambers L, Jernigan AM, Freeman L, Escobar PF, Michener CM.
    • Int J Gynecol Cancer. 2020 Sep 18:ijgc-2020-001405. doi: 10.1136/ijgc-2020-001405. Epub ahead of print.
    • Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes.
    • Pietragalla A, Arcieri M, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Sep 6:ijgc-2020-001556. doi: 10.1136/ijgc-2020-001556. Epub ahead of print.
    • Review
    • Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.
    • Watson CH, Soo L, Davidson BA, Havrilesky LJ, Lee PS, McNally LJ, Previs RA, Secord AA, Berchuck A, Kauff ND.
    • Int J Gynecol Cancer. 2020 Aug 23:ijgc-2020-001536. doi: 10.1136/ijgc-2020-001536. Epub ahead of print.
    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.
    • Attitudes towards risk-reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study.
    • Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C, Izatt L, Tripathi V, Esteban I, McNicol L, Ragupathy K, Crawford R, Evans DG, Legood R, Menon U, Manchanda R.
    • BJOG. 2020 Aug 16. doi: 10.1111/1471-0528.16424. Epub ahead of print.

    Commentary:

    Attitudes towards risk-reducing salpingectomy: listen to the patients.

    Press: Two-Stage Surgery to Reduce Ovarian Cancer Risk Piques Interest (Medscape. News & Perspective.)

    Research news: Study: Women support delayed removal of ovaries (FORCE. XRAY.)

    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.
    • Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers.
    • Mejia-Gomez J, Gronwald J, Senter L, Karlan BY, Tung N, Wolfman W, Demsky R, Sun P, Narod SA, Kotsopoulos J; and the Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2020 Aug 10. doi: 10.1097/GME.0000000000001629. Epub ahead of print.
    • Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) for prophylactic bilateral salpingo-oophorectomy.
    • Goldenberg M, Burke YZ, Matanes E, Lowenstein L.
    • Surg Oncol. 2020 Aug 6;35:79-80. doi: 10.1016/j.suronc.2020.07.006. Epub ahead of print.
    • Case report
    • BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic literature review.
    • Merlino L, Chiné A, Galli C, Piccioni MG.
    • Minerva Ginecol. 2020 Aug 3. doi: 10.23736/S0026-4784.20.04624-9. Epub ahead of print.
    • Review
    • Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
    • Chen J, Bae E, Zhang L, Hughes K, Parmigiani G, Braun D, Rebbeck TR.
    • JNCI Cancer Spectr. 2020 Apr 23 [eCollection 2020 Aug.];4(4):pkaa029. doi: 10.1093/jncics/pkaa029.
    • Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.
    • Silva Filho ALD, Carvalho GM, Sena LC, Gomes LPG, Valério MFH, Martins RIL, Cândido EB.
    • Rev Assoc Med Bras (1992). 2020 Aug;66(8):1134-1138. doi: 10.1590/1806-9282.66.8.1134.
    • Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature.
    • Palaiologos K, Ellaboudy A, Abdullah M, Karan S, Saha A.
    • Cureus. 2020 Jul 20;12(7):e9301. doi: 10.7759/cureus.9301.
    • BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
    • Kitson SJ, Bafligil C, Ryan NAJ, Lalloo F, Woodward ER, Clayton RD, Edmondson RJ, Bolton J, Crosbie EJ, Evans GD.
    • Eur J Cancer. 2020 Jul 19;136:169-175. doi: 10.1016/j.ejca.2020.05.030. Epub ahead of print.
    • Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database.
    • Dominguez-Valentin M, Seppälä TT, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W, Vangala D, Perne C, Strauß HG, Tecklenburg J, Holinski-Feder E, Steinke-Lange V, Mecklin JP, Plazzer JP, Pineda M, Navarro M, Vidal JB, Kariv R, Rosner G, Piñero TA, Gonzalez ML, Kalfayan P, Sampson JR, Ryan NAJ, Evans DG, Møller P, Crosbie EJ.
    • J Clin Med. 2020 Jul 18;9(7):2290. doi: 10.3390/jcm9072290.
    • Minilaparoscopic single-site bilateral salpingo-oophorectomy: a scarless prophylactic procedure.
    • Casarin J, Laganà AS, Pinelli C, Cromi A, Ghezzi F.
    • Minim Invasive Ther Allied Technol. 2020 Jul 16:1-6. doi: 10.1080/13645706.2020.1790391. Epub ahead of print.
    • Case report
    • Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
    • Collins JM, Isaacs C.
    • Breast J. 2020 Jul 11. doi: 10.1111/tbj.13970. Epub ahead of print.
    • Review
    • Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines.
    • Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E, Van Gorp T, Vanderstichele A, Van Ongeval C, Keupers M, Prevos R, Celis V, Dekervel J, Everaerts W, Wildiers H, Nevelsteen I, Neven P, Timmerman D, Smeets A, Denayer E, Van Buggenhout G, Legius E, Punie K.
    • J Oncol. 2020 Jun 20;2020:9873954. doi: 10.1155/2020/9873954.
    • The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: a prospective cohort, other biomarker controlled, study.
    • Grandi G, Del Savio MC, Sammarini M, Cortesi L, Toss A, Piombino C, Facchinetti F.
    • Eur J Cancer Prev. 2020 Jun 8. doi: 10.1097/CEJ.0000000000000606. Epub ahead of print.
    • Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer.
    • Mainor CB, Isaacs C.
    • Curr Breast Cancer Rep. 2020 Jun;12(2):66-74. doi: 10.1007/s12609-019-00350-2. Epub 2020 Feb 17.
    • Review
    • Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
    • Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole I, Broach V, Chi DS.
    • Obstet Gynecol. 2020 Jun;135(6):1270-1274. doi: 10.1097/AOG.0000000000003864.
    • Case report

    Editorial:

    Too Good to Be True.

    • Patients Having Ovaries Removed Without Clear Genetic, Medical Rationale, Study Suggests.
    • Ray T.
    • Precision Oncology News. 2020 May 29.
    • Factors associated with counseling and postoperative hormone therapy use in surgically menopausal women.
    • Verrilli L, Brown H, Williams M.
    • Menopause. 2020 May 11. doi: 10.1097/GME.0000000000001560. Epub ahead of print.
    • Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA.
    • Int J Gynecol Cancer. 2020 Apr 30. pii: ijgc-2019-001141. doi: 10.1136/ijgc-2019-001141. [Epub ahead of print]
    • Cognitive markers of dementia risk in middle-aged women with bilateral salpingo-oophorectomy prior to menopause.
    • Gervais NJ, Au A, Almey A, Duchesne A, Gravelsins L, Brown A, Reuben R, Baker-Sullivan E, Schwartz DH, Evans K, Bernardini MQ, Eisen A, Meschino WS, Foulkes WD, Hampson E, Einstein G.
    • Neurobiol Aging. 2020 Apr 29;94:1-6. doi: 10.1016/j.neurobiolaging.2020.04.019. Epub ahead of print.
    • Hormone Therapy Use After Premature Surgical Menopause Based on Prescription Records: A Population-Based Study.
    • Jang JH, Arora N, Kwon JS, Hanley GE.
    • J Obstet Gynaecol Can. 2020 Apr 27:S1701-2163(20)30336-4. doi: 10.1016/j.jogc.2020.03.022. Epub ahead of print.
    • Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
    • Grandi G, Caroli M, Alboni C, Cortesi L, Toss A, Barbieri E, Botticelli L, Facchinetti F.
    • Fam Cancer. 2020 Apr 24. doi: 10.1007/s10689-020-00179-0. [Epub ahead of print]
    • Case report
    • Risk of cardiovascular disease after preventive salpingo-oophorectomy.
    • Johansen N, Tonstad S, Liavaag AH, Selmer RM, Tanbo TG, Michelsen TM.
    • Int J Gynecol Cancer. 2020 Apr 23. pii: ijgc-2019-000856. doi: 10.1136/ijgc-2019-000856. [Epub ahead of print]
    • Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
    • Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, Teule A, Brunet J, Y Cajal TR, Llort G, Dienstmann R, Rue M, Domchek SM, Balmaña J.
    • Eur J Cancer. 2020 Apr 20;132:53-60. doi: 10.1016/j.ejca.2020.03.009. [Epub ahead of print]
    • Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    • Hurry M, Eccleston A, Dyer M, Hoskins P
    • Int J Technol Assess Health Care. 2020 Apr;36(2):104-112. doi: 10.1017/S0266462319003519.
    • Future Research Suggestions for Multigene Testing in Unselected Populations.
    • Jun I, Berger AL, Yaghjyan L.
    • JAMA Oncol. 2020 Mar 26. doi: 10.1001/jamaoncol.2020.0128. [Epub ahead of print]
    • Letter, Comment

    Original research:

    A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

    Letter, Reply:

    Future Research Suggestions for Multigene Testing in Unselected Populations-Reply.

    • Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    • Rush SK, Swisher EM, Garcia RL, Pennington KP, Agnew KJ, Kilgore MR, Norquist BM.
    • Gynecol Oncol. 2020 Mar 18. pii: S0090-8258(20)30101-3. doi: 10.1016/j.ygyno.2020.02.006. [Epub ahead of print]
    • Executive function after risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: does current mood and early life adversity matter?
    • Shanmugan S, Sammel MD, Loughead J, Ruparel K, Gur RC, Brown TE, Faust J, Domchek S, Epperson CN.
    • Menopause. 2020 Mar 16. doi: 10.1097/GME.0000000000001535. [Epub ahead of print]
    • Updated Guideline Moves Genetic Testing Beyond BRCA.
    • Narozniak R.
    • OncologyLive. 2020 Mar 13;21(6).
    • News

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
    • Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH.
    • Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30179-7. doi: 10.1016/j.ygyno.2020.02.033. [Epub ahead of print]
    • Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
    • Ghezelayagh TS, Stewart LE, Norquist BM, Bowen DJ, Yu V, Agnew KJ, Pennington KP, Swisher EM.
    • Fam Cancer. 2020 Feb 24. doi: 10.1007/s10689-020-00166-5. [Epub ahead of print]
    • Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    • Printz C.
    • Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician.
    • Bachert SE, McDowell A Jr, Piecoro D, Baldwin Branch L.
    • Diagnostics (Basel). 2020 Feb 13;10(2). pii: E102. doi: 10.3390/diagnostics10020102.
    • Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    • Kotsopoulos J, Narod SA.
    • Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916. [Epub ahead of print]
    • Review
    • Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    • Gaba F, Manchanda R.
    • Best Pract Res Clin Obstet Gynaecol. 2020 Feb 4. pii: S1521-6934(20)30018-3. doi: 10.1016/j.bpobgyn.2020.01.006. [Epub ahead of print]
    • The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
    • Rudaitis V, Mikliusas V, Januska G, Jukna P, Mickys U, Janavicius R.
    • Eur J Obstet Gynecol Reprod Biol. 2020 Jan 30;247:26-31. doi: 10.1016/j.ejogrb.2020.01.040. [Epub ahead of print]
    • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    • Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA; GENEPSO, Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A; EMBRACE, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D; HEBON, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS; kConFab Investigators, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF; IBCCS; kConFab; BCFR.
    • Breast Cancer Res. 2020 Jan 16;22(1):8. doi: 10.1186/s13058-020-1247-4.
    • Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
    • Powell CB, Littell RD, Landen CN Jr, Pramanik S, Hamilton IC, Suh-Burgmann EJ.
    • Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31847-5. doi: 10.1016/j.ygyno.2019.12.026. [Epub ahead of print]
    • Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    • Solsky I, Chen J, Rebbeck TR.
    • Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31695-6. doi: 10.1016/j.ygyno.2019.11.036. [Epub ahead of print]
    • Risk-Reducing Bilateral Salpingo-Oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    • Newcomb LK, Toal CT, Rindos NB, Wang L, Mansuria SM.
    • J Minim Invasive Gynecol. 2020 Jan 9. pii: S1553-4650(20)30037-6. doi: 10.1016/j.jmig.2020.01.004. [Epub ahead of print]
    • SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
    • González-Santiago S, Ramón Y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-Del-Alba A; SEOM Hereditary Cancer Working Group.
    • Clin Transl Oncol. 2019 Dec 30. doi: 10.1007/s12094-019-02262-0. [Epub ahead of print]
    • Peritoneal cancer after bilateral mastectomy, hysterectomy, and bilateral salpingo-oophorectomy with a poor prognosis: A case report and review of the literature.
    • Ma YN, Bu HL, Jin CJ, Wang X, Zhang YZ, Zhang H.
    • World J Clin Cases. 2019 Nov 26;7(22):3872-3880. doi: 10.12998/wjcc.v7.i22.3872.
    • The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies.
    • Kyo S, Ishikawa N, Nakamura K, Nakayama K.
    • Cancer Med. 2019 Nov 25. doi: 10.1002/cam4.2725. [Epub ahead of print]
    • Preventing Ovarian Cancer in High-risk Women: One Surgery at a Time.
    • Swanson CL, Bakkum-Gamez JN.
    • Clin Obstet Gynecol. 2019 Nov 22. doi: 10.1097/GRF.0000000000000499. [Epub ahead of print]
    • Review
    • Breast cancer prevention in high-risk women.
    • Thorat MA, Balasubramanian R.
    • Best Pract Res Clin Obstet Gynaecol. 2019 Nov 21. pii: S1521-6934(19)30170-1. doi: 10.1016/j.bpobgyn.2019.11.006. [Epub ahead of print]
    • Review
    • Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    • Mai PL, Huang HQ, Wenzel LB, Han PK, Moser RP, Rodriguez GC, Boggess J, Rutherford TJ, Cohn DE, Kauff ND, Phillips KA, Wilkinson K, Wenham RM, Hamilton C, Powell MA, Walker JL, Greene MH, Hensley ML.
    • Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613-0. doi: 10.1016/j.ygyno.2019.10.026. [Epub ahead of print]
    • Use of antidepressants in women after prophylactic bilateral oophorectomy: A Danish national cohort study.
    • Abildgaard J, Ahlström MG, Nielsen DL, Daugaard G, Lindegaard B, Obel N, Lidegaard Ø.
    • Psychooncology. 2019 Nov 16. doi: 10.1002/pon.5290. [Epub ahead of print]
    • Transvaginal laparoscopic salpingo-oophorectomy: an oncological risk-reducing procedure.
    • Lathouras K, Saso S, Jones BP, Bowden S, Kyrgiou M, Stienen-Durand A, Beynon G.
    • Future Sci OA. 2019 Nov 5;6(1):FSO429. doi: 10.2144/fsoa-2019-0089.
    • Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    • Perri T, Farhadian Y, Friedman E, Korach J.
    • Menopause. 2019 Nov 4. doi: 10.1097/GME.0000000000001432. [Epub ahead of print]
    • Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
    • Powell CB, Alabaster A, Le A, Stoller N, Armstrong MA, Raine-Bennett T.
    • Psychooncology. 2019 Oct 26. doi: 10.1002/pon.5253. [Epub ahead of print]
    • Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
    • Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N, Eng C, Karlan B, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Menopause. 2019 Oct 21. doi: 10.1097/GME.0000000000001437. [Epub ahead of print]
    • Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
    • Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.
    • Menopause. 2019 Oct 14. doi: 10.1097/GME.0000000000001422. [Epub ahead of print]
    • Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).
    • Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
    • JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb.

    Commentary:

    Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?

    • Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
    • Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M.
    • Cochrane Database Syst Rev. 2019 Oct 9;10:CD012894. doi: 10.1002/14651858.CD012894.pub2. [Epub ahead of print]
    • Review

    Original research:

    Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.

    Original research:

    Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.

    • A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    • Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

    CME Audio Interview: Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer. (JN Learning : JAMA Oncology)

    Press: Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients. (GenomeWeb)

    Letter, Comment:

    Future Research Suggestions for Multigene Testing in Unselected Populations.

    Letter, Reply:

    Future Research Suggestions for Multigene Testing in Unselected Populations—Reply.

    • Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening Wider.
    • Robson M, Domchek S.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.4004. [Epub ahead of print]
    • Commentary
    • What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
    • Hickey M, Rio I, Trainer A, Marino JL, Wrede CD, Peate M.
    • Menopause. 2019 Sep 16. doi: 10.1097/GME.0000000000001421. [Epub ahead of print]
    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    • Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim S, Kotsopoulos J, Narod SA.
    • Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486-6. doi: 10.1016/j.ygyno.2019.08.034. [Epub ahead of print]
    • Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    • Cheng A, Li L, Wu M, Lang J.
    • Eur J Surg Oncol. 2019 Sep 5. pii: S0748-7983(19)30662-6. doi: 10.1016/j.ejso.2019.09.002. [Epub ahead of print]
    • Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
    • Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK.
    • Obstet Gynecol. 2019 Sep;134(3):520-526. doi: 10.1097/AOG.0000000000003421.
    • Hysterectomy and Adenextomy via transvaginal natural orifice transluminal endoscopic surgery (vNOTES): A UK perspective with a case series of 33 patients.
    • Karkia R, Giacchino T, Taylor J, Ghaffar A, Gupta A, Kovoor E.
    • Eur J Obstet Gynecol Reprod Biol. 2019 Aug 31;242:29-32. doi: 10.1016/j.ejogrb.2019.08.023. [Epub ahead of print]
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.
    • Walker M, Jacobson M, Sobel M.
    • CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.
    • Peritoneal involvement by salpingoliths clinical significance and cytological challenges of interpretation.
    • El Hussein S, Guerrero D, Khader SN.
    • Diagn Cytopathol. 2019 Aug 7. doi: 10.1002/dc.24299. [Epub ahead of print]
    • Case report
    • Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation.
    • Kotsopoulos J, Hall E, Finch A, Hu H, Murphy J, Rosen B, Narod SA, Cheung AM.
    • JAMA Netw Open. 2019 Aug 2;2(8):e198420. doi: 10.1001/jamanetworkopen.2019.8420.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer.
    • Bercow AS, Eisenhauer EL.
    • J Surg Oncol. 2019 Jul 29. doi: 10.1002/jso.25645. [Epub ahead of print]
    • Review
    • Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    • Gasparri ML, Taghavi K, Fiacco E, Zuber V, Di Micco R, Gazzetta G, Valentini A, Mueller MD, Papadia A, Gentilini OD.
    • Medicina (Kaunas). 2019 Jul 29;55(8). pii: E415. doi: 10.3390/medicina55080415.
    • Laparoscopic intra-operative ultrasound-guided bilateral salpingo-oophorectomy in a BRCA2 mutated patient.
    • Bruno M, De Blasis I, Marinucci B, Testa AC, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Jul 17. pii: ijgc-2019-000530. doi: 10.1136/ijgc-2019-000530. [Epub ahead of print]
    • Contemporary management of adnexa at the time of benign hysterectomy: a review of the literature.
    • Tamhane N, Imudia AN, Mikhail E.
    • J Obstet Gynaecol. 2019 Jul 13:1-7. doi: 10.1080/01443615.2019.1581747. [Epub ahead of print]
    • Review
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations?
    • Markman M.
    • Medscape Oncology. 2019 Jun 14.

    Original research:

    Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

    • [Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.]
    • Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.
    • Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary.
    • Gaba F, Piek J, Menon U, Manchanda R.
    • BJOG. 2019 Jun;126(7):831-839. doi: 10.1111/1471-0528.15651. Epub 2019 Mar 14.
    • Commentary
    • Women's health 2019: Osteoporosis, breast cancer, contraception, and hormone therapy.
    • Moreno AC, Sahni SK, Smith TL, Batur P.
    • Cleve Clin J Med. 2019 Jun;86(6):400-406. doi: 10.3949/ccjm.86a.18130.
    • Concurrent hysterectomy at the tine of risk-reducing surgery for patients with BRCA mutations.
    • Gordhandas S, Ruiz MP, Talukdar N, Holcomb KM, Freya MK, Chapman-Davis E, Kahn RM.
    • Gynecol Oncol. 2019 Jun;153(3):e12-e13. doi: 10.1016/j.ygyno.2019.03.134.
    • Conference abstract
    • Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: rationale and design of the harmony study.
    • Terra L, Hooning MJ, Heemskerk-Gerritsen BAM, Maas AHEM, van Leeuwen FE, HARMOny investigators.
    • Maturitas. 2019 Jun;124:159-160. doi: 10.1016/j.maturitas.2019.04.136.
    • Conference abstract, Review
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    • Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.
    • J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.
    • Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?
    • Catanzarite T, Eskander RN.
    • Female Pelvic Med Reconstr Surg. 2019 May 22. doi: 10.1097/SPV.0000000000000741. [Epub ahead of print]
    • Review
    • Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.
    • Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S.
    • Int J Clin Oncol. 2019 May 4. doi: 10.1007/s10147-019-01456-4. [Epub ahead of print]
    • Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    • Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC.
    • Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.
    • An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
    • Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.
    • Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]
    • Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).
    • Ahmed F, Christos PJ, Singh P, Parashar B, Wernicke AG.
    • Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000542. [Epub ahead of print]
    • Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2
    • Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM.
    • Gynecol Oncol. 2019 Apr;153(1):192-200. doi: 10.1016/j.ygyno.2018.12.014. Epub 2019 Jan 17.
    • Review

    Commentary: How Safe Is Hormone Replacement Therapy After Risk-Reducing Salpingo-oophorectomy in Women With BRCA Mutations? (Medscape Oncology)

    • Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
    • Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV.
    • Climacteric. 2019 Mar 25:1-9. doi: 10.1080/13697137.2019.1582622. [Epub ahead of print]
    • Review
    • Surgery to Reduce Ovarian Cancer Risk — One Step or Two?
    • Harrison P
    • Medscape. Medscape Oncology. 2019 Mar 25.
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.
    • Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, Dite GS, MacInnis RJ, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, Weideman PC, Glendon G, Buchsbaum R, Andrulis IL, John EM, Buys SS, Hopper JL.
    • J Natl Cancer Inst. 2019 Mar 1;111(3):331-334. doi: 10.1093/jnci/djy182.

    Press: Oophorectomy to Reduce Ovarian-cancer Risk Not Tied to Breast-cancer Risk. (Medscape Oncology)

    • BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    • Kwon JS, Tinker AV, Hanley GE, Pansegrau G, Sun S, Carey MS, Schrader I.
    • Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • Risk Reduction and Survival Benefit of Risk-Reducing Salpingo-oophorectomy in Hereditary Breast Cancer: Meta-analysis and Systematic Review.
    • Xiao YL, Wang K, Liu Q, Li J, Zhang X, Li HY.
    • Clin Breast Cancer. 2019 Feb;19(1):e48-e65. doi: 10.1016/j.clbc.2018.09.011. Epub 2018 Oct 4.
    • Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
    • AlHilli MM, Al-Hilli Z.
    • J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19.
    • Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy.
    • Chan JL, Senapati S, Johnson LNC, DiGiovanni L, Voong C, Butts SF, Domchek SM.
    • Menopause. 2019 Feb;26(2):132-139. doi: 10.1097/GME.0000000000001176.
    • Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    • Hoskins P, Eccleston A, Hurry M, Dyer M.
    • Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061-7. doi: 10.1016/j.ygyno.2019.01.018. [Epub ahead of print]
    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration.
    • Zeydan B, Tosakulwong N, Schwarz CG, Senjem ML, Gunter JL, Reid RI, Gazzuola Rocca L, Lesnick TG, Smith CY, Bailey KR, Lowe VJ, Roberts RO, Jack CR Jr, Petersen RC, Miller VM, Mielke MM, Rocca WA, Kantarci K.
    • JAMA Neurol. 2019 Jan 1;76(1):95-100. doi: 10.1001/jamaneurol.2018.3057.
    • Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
    • Teixeira N, Mourits MJ, Oosterwijk JC, Fakkert IE, Absalom AR, Bakker SJL, van der Meer P, de Bock GH.
    • Fam Cancer. 2019 Jan;18(1):19-27. doi: 10.1007/s10689-018-0091-5.
    • Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    • Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J.
    • Gynecol Oncol. 2019 Jan;152(1):145-150. doi: 10.1016/j.ygyno.2018.10.040. Epub 2018 Nov 7.
    • Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
    • Vermeulen RFM, van Beurden M, Gaarenstroom KN, Teunis T, Kieffer JM, Aaronson NK, Kenter GG, Korse CM.
    • Climacteric. 2018 Dec;21(6):574-580. doi: 10.1080/13697137.2018.1512965. Epub 2018 Oct 8.
    • Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations.
    • Powell CB, Alabaster A, Armstrong MA, Stoller N, Raine-Bennett T.
    • Gynecol Oncol. 2018 Dec;151(3):489-493. doi: 10.1016/j.ygyno.2018.10.010. Epub 2018 Oct 10.
    • An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section.
    • Lee CM, Moh M, Sullivan PS, Moatamed NA.
    • Case Rep Pathol. 2018 Nov 21;2018:8148147. doi: 10.1155/2018/8148147. eCollection 2018.
    • Cancer Risk-Reducing Opportunities in Gynecologic Surgery.
    • Piszczek C, Ma J, Gould CH, Tseng P.
    • J Minim Invasive Gynecol. 2018 Nov - Dec;25(7):1179-1193. doi: 10.1016/j.jmig.2017.10.025. Epub 2017 Oct 31.
    • Review
    • Hysterectomy at the time of risk-reducing surgery in BRCA carriers.
    • Nair N, Schwartz M, Guzzardi L, Durlester N, Pan S, Overbey J, Chuang L.
    • Gynecol Oncol Rep. 2018 Oct 6;26:71-74. doi: 10.1016/j.gore.2018.10.003. eCollection 2018 Nov.
    • Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.
    • Jatoi I.
    • Eur J Breast Health. 2018 Oct 1;14(4):189-193. doi: 10.5152/ejbh.2018.4324. eCollection 2018 Oct.

    Letter, Review:

    What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.

    • Surgical prevention strategies in ovarian cancer.
    • Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS.
    • Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
    • Review
    • Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation.
    • [No author given]
    • FORCE. XRAYS. 2018 Sep 7.

    Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.

    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    • Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.
    • Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464. doi: 10.1002/14651858.CD012464.pub2.
    • Meta-Analysis, Review
    • Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
    • Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • JAMA Oncol. 2018 Aug 1;4(8):1059-1065. doi: 10.1001/jamaoncol.2018.0211.

    Research News: Hormone therapy and breast cancer risk after ovary removal in women with a BRCA1 mutation. (FORCE, XRAYS)

    Commentary, Video: Menopausal Hormone Therapy and Risk for Breast Cancer in BRCA1 Mutation Carriers. (Medscape)

    • Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    • Elmi M, Azin A, Elnahas A, McCready DR, Cil TD.
    • Breast Cancer Res Treat. 2018 Aug;171(1):217-223. doi: 10.1007/s10549-018-4818-7. Epub 2018 May 14.
    • Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    • Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22.
    • Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
    • Casey MJ, Salzman TA.
    • Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.
    • Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer.
    • Abildgaard J, Ahlström MG, Daugaard G, Nielsen DL, Tønnes Pedersen A, Lindegaard B, Obel N.
    • JNCI Cancer Spectrum. 2018 Jul 1;2(3):pky034. doi: 10.1093/jncics/pky034.
    • Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    • Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH.
    • Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018 May 4.
    • Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.
    • Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.
    • Wong S, Ratner E, Buza N.
    • Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.
    • Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
    • Johansen N, Liavaag AH, Mørkrid L, Michelsen TM.
    • Sex Med. 2018 Jun;6(2):143-153. doi: 10.1016/j.esxm.2018.02.002. Epub 2018 Apr 7.
    • Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    • Stuursma A, van Driel CMG, Wessels NJ, de Bock GH, Mourits MJE.
    • Maturitas. 2018 May;111:69-76. doi: 10.1016/j.maturitas.2018.01.012. Epub 2018 Jan 13.
    • Ovarian Cancer Prevention and Screening.
    • Menon U, Karpinskyj C, Gentry-Maharaj A.
    • Obstet Gynecol. 2018 May;131(5):909-927. doi: 10.1097/AOG.0000000000002580.
    • Review
    • Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease.
    • Batulan Z, Maarouf N, Shrivastava V, O'Brien E.
    • Womens Midlife Health. 2018 Apr 27;4:7. doi: 10.1186/s40695-018-0037-y. eCollection 2018.
    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • Does oophorectomy reduce breast cancer mortality for BRCA mutation carriers after breast cancer?
    • Jacobson M, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Apr;18(4):305-306. doi: 10.1080/14737140.2018.1438891. Epub 2018 Feb 16.
    • [Cost-effectiveness of risk-reducing salpingo-oophorectomy in cases of BRCA1 gene mutation in Colombia].
    • González-Mariño MA.
    • Rev Salud Publica (Bogota). 2018 Mar-Apr;20(2):232-236. doi: 10.15446/rsap.V20n2.64866.
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    • Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME.
    • Gynecol Oncol. 2018 Mar;148(3):515-520. doi: 10.1016/j.ygyno.2018.01.016.
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis.
    • Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.
    • Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer.
    • Manchanda R, Menon U.
    • Int J Gynecol Cancer. 2018 Jan;28(1):34-42. doi: 10.1097/IGC.0000000000001147.
    • Vaginal Salpingectomy Techniques in the Presence of Ovarian Conservation.
    • Cornella JL.
    • J Minim Invasive Gynecol. 2018 Jan;25(1):16. doi: 10.1016/j.jmig.2017.06.012. Epub 2017 Jun 21.
    • Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.
    • Harvey LFB, Abramson VG, Alvarez J, DeStephano C, Hur HC, Lee K, Mattingly P, Park B, Piszczek C, Seifi F, Stuparich M, Yunker A.
    • J Minim Invasive Gynecol. 2018 Jan;25(1):111-115. doi: 10.1016/j.jmig.2017.08.643. Epub 2017 Aug 15.
    • Surveillance report 2018 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164 [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Murray A.
    • London: National Institute for Health and Care Excellence (UK); 2018 Jan.

    • A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
    • Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D.
    • Int J Surg Case Rep. 2018;52:107-110. doi: 10.1016/j.ijscr.2018.10.014. Epub 2018 Oct 12.
    • [Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
    • Steenbeek MP, Bulten J, Hoogerbrugge N, Massuger LFAG, Pijnenborg JMA, de Hullu JA.
    • Ned Tijdschr Geneeskd. 2018;162(0):D2337.
    • Case report, [Article in Dutch]
    • "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".
    • Malacarne DR, Boyd LR, Long Y, Blank SV.
    • World J Surg Oncol. 2017 Dec 11;15(1):218. doi: 10.1186/s12957-017-1282-5.
    • Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2017 Dec;296(6):1055-1062. doi: 10.1007/s00404-017-4529-z. Epub 2017 Sep 23.
    • Review
    • Prophylactic Surgery: For Whom, When and How?
    • Mau C, Untch M.
    • Breast Care (Basel). 2017 Dec;12(6):379-384. doi: 10.1159/000485830. Epub 2017 Dec 13.
    • Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.
    • De Felice F, Marchetti C, Boccia SM, Romito A, Sassu CM, Porpora MG, Muzii L, Tombolini V, Benedetti Panici P.
    • Cancer Treat Rev. 2017 Dec;61:1-5. doi: 10.1016/j.ctrv.2017.09.005. Epub 2017 Sep 28.
    • Review
    • Sexual Health Is Paramount in the Counseling of Women at Risk for Breast or Ovarian Cancer Undergoing Risk-Reducing Surgery.
    • Rullo JE, Pruthi S.
    • J Natl Compr Canc Netw. 2017 Nov 1;15(11):1297. doi: 10.6004/jnccn.2017.7016.
    • Commentary
    • Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy".
    • Bogani G, Signorelli M, Chiappa V, Carcangiu ML, Martinelli F, Paolini B, Leone Roberti Maggiore U, Gennaro M, Borghi C, Scaffa C, Ditto A, Lorusso D, Raspagliesi F.
    • J Minim Invasive Gynecol. 2017 Nov - Dec;24(7):1243-1244. doi: 10.1016/j.jmig.2017.05.020. Epub 2017 Jun 23.
    • Letter

    Letter:

    Author's Reply.

    • Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
    • Hoskins PJ, Gotlieb WH.
    • CA Cancer J Clin. 2017 Nov;67(6):493-506. doi: 10.3322/caac.21408. Epub 2017 Sep 7.
    • BRCA and lynch syndrome-associated ovarian cancers behave differently.
    • Ryan NAJ, Bolton J, McVey RJ, Evans DG, Crosbie EJ.
    • Gynecol Oncol Rep. 2017 Nov 22;22:108-109. doi: 10.1016/j.gore.2017.11.007. eCollection 2017 Nov.

    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.

    Letter: Ovarian carcinoma histotype in Lynch syndrome. (Gynecologic Oncology Reports)

    • Ovarian Cancer Prevention, Screening, and Early Detection: Report From the 11th Biennial Ovarian Cancer Research Symposium.
    • Chien J, Poole EM.
    • Int J Gynecol Cancer. 2017 Nov;27(9S Suppl 5):S20-S22. doi: 10.1097/IGC.0000000000001118.
    • Conference report
    • RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    • Nolan E, Vaillant F, Visvader JE, Lindeman GJ.
    • J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx038.
    • Letter

    Letter, Reply:

    Response.

    • The Evolution of and Evidence for Opportunistic Salpingectomy.
    • Dilley SE, Straughn JM Jr, Leath CA 3rd.
    • Obstet Gynecol. 2017 Oct;130(4):814-824. doi: 10.1097/AOG.0000000000002243.
    • Review
    • Dynamic real-time in vivo confocal laser endomicroscopy of the fallopian tube during laparoscopy in the prevention of ovarian cancer.
    • Chene G, Chauvy L, Buenerd A, Moret S, Nadaud B, Chabert P, Lamblin G.
    • Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:18-23. doi: 10.1016/j.ejogrb.2017.07.002. Epub 2017 Jul 5.
    • LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
    • Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.
    • Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.
    • Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.
    • Balsarkar G.
    • J Obstet Gynaecol India. 2017 Aug;67(4):243-246. doi: 10.1007/s13224-017-0998-z. Epub 2017 May 11.
    • Risk Reduction Strategies in Breast Cancer Prevention.
    • Costa M, Saldanha P.
    • Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.
    • Impact of risk-reducing salpingo-oophorectomy in premenopausal women.
    • Vermeulen RFM, Beurden MV, Korse CM, Kenter GG.
    • Climacteric. 2017 Jun;20(3):212-221. doi: 10.1080/13697137.2017.1285879. Epub 2017 Mar 2.
    • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    • Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND.
    • Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.
    • Salvador S, Scott S, Francis JA, Agrawal A, Giede C.
    • J Obstet Gynaecol Can. 2017 Jun;39(6):480-493. doi: 10.1016/j.jogc.2016.12.005.
    • Practice Guideline, Review

    Practice Guideline, Review, [Article in French]:

    No 344-Salpingectomie opportuniste et autres méthodes pour réduire le risque de cancer de l'ovaire, de la trompe de Fallope et du péritoine dans la population générale.

    • No 344-Salpingectomie opportuniste et autres méthodes pour réduire le risque de cancer de l'ovaire, de la trompe de Fallope et du péritoine dans la population générale.
    • Salvador S, Scott S, Francis JA, Agrawal A, Giede C.
    • J Obstet Gynaecol Can. 2017 Jun;39(6):494-508. doi: 10.1016/j.jogc.2017.03.121.
    • Practice Guideline, Review, [Article in French]

    Practice Guideline, Review, English Abstract:

    No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.

    • Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.
    • Pérez-López FR, Ceausu I, Depypere H, Kehoe S, Lambrinoudaki I, Mueck A, Senturk LM, Simoncini T, Stevenson JC, Stute P, Rees M.
    • Maturitas. 2017 Jun;100:86-91. doi: 10.1016/j.maturitas.2017.03.003. Epub 2017 Mar 15.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 May 12. doi: 10.1097/IGC.0000000000000964. [Epub ahead of print]
    • Ovarian carcinoma histotype in Lynch syndrome.
    • Gilks CB, Clarke BA, Foulkes WD.
    • Gynecol Oncol Rep. 2017 Mar 16;20:140-141. doi: 10.1016/j.gore.2017.03.009. eCollection 2017 May.

    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.

    Letter:

    BRCA and lynch syndrome-associated ovarian cancers behave differently.

    • Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Breast. 2017 Apr;32:186-191. doi: 10.1016/j.breast.2017.02.008. Epub 2017 Feb 17.
    • Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.
    • Tschernichovsky R, Goodman A.
    • Oncologist. 2017 Apr;22(4):450-459. doi: 10.1634/theoncologist.2016-0444. Epub 2017 Mar 17.
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    • Ryan NA, Evans DG, Green K, Crosbie EJ.
    • Gynecol Oncol. 2017 Mar;144(3):491-495. doi: 10.1016/j.ygyno.2017.01.005. Epub 2017 Jan 6.

    Letter: Ovarian carcinoma histotype in Lynch syndrome. (Gynecologic Oncology Reports)

    Letter:

    BRCA and lynch syndrome-associated ovarian cancers behave differently.

    • [Clinical Management of HBOC in Our Hospital].
    • Nomura H, Takeshima N.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):116-120.
    • [Article in Japanese]
    • In-hospital complications of bilateral salpingo-oophorectomy at benign hysterectomy: a population-based cohort study.
    • Lai JC, Chen HH, Chu KH, Wang KL, Huang N, Hu HY, Chou YJ.
    • Menopause. 2017 Feb;24(2):187-195. doi: 10.1097/GME.0000000000000746.
    • Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    • Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, Slart RH, Westrik IG, de Bock GH, Mourits MJ.
    • PLoS One. 2017 Jan 6;12(1):e0169673. doi: 10.1371/journal.pone.0169673. eCollection 2017.
    • Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.
    • Ma IT, Gray RJ, Wasif N, Butler KA, Cornella JL, Magrina JF, Magtibay PM, Casey WJ, Mahabir R, Rebecca AM, Hunt KS, Pockaj BA.
    • Ann Surg Oncol. 2017 Jan;24(1):77-83. doi: 10.1245/s10434-016-5479-6. Epub 2016 Aug 31.
    • The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    • Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.
    • Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.
    • Non-Neoplastic Conditions of the Ovaries in Grossly Normal Adnexa: A Clinicopathologic Study of 403 Completely Embedded Cases.
    • Seidman JD, Krishnan J.
    • Int J Gynecol Pathol. 2016 Nov;35(6):544-548.
    • Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
    • Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL.
    • Am J Surg. 2016 Oct;212(4):660-669. doi: 10.1016/j.amjsurg.2016.06.010. Epub 2016 Jul 18.
    • Review
    • Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future.
    • Pérez-López FR, Chedraui P.
    • Climacteric. 2016 Oct;19(5):417-8. doi: 10.1080/13697137.2016.1202914. Epub 2016 Jul 12.
    • Risk-reducing surgery on the uterine adnexa: timing and type of surgical treatment, and pathology report.
    • Signorelli M, Bogani G, Ditto A, Martinelli F, Chiappa V, Lopez C, Scaffa C, Lorusso D, Raspagliesi F.
    • Minerva Ginecol. 2016 Oct;68(5):536-43. Epub 2016 Feb 4.
    • Review
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • [Salpingectomy in ovarian cancer prevention: Evidence behind the hypothesis and surgical implications].
    • Gómez-Pue D, Ibarrola-BuenAbad E, Lara-Núñez D, Vázquez-Alvarado AP, Pérez-Quintanilla M.
    • Ginecol Obstet Mex. 2016 Sep;84(9):614-9.
    • Review, [Article in Spanish]
    • Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
    • Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U.
    • J Med Genet. 2016 Sep;53(9):591-9. doi: 10.1136/jmedgenet-2016-103800. Epub 2016 Jun 27.
    • [Current surgical practice of prophylactic and opportunistic salpingectomy in France].
    • Chene G, de Rochambeau B, Le Bail-Carval K, Beaufils E, Chabert P, Mellier G, Lamblin G.
    • Gynecol Obstet Fertil. 2016 Jul-Aug;44(7-8):377-84. doi: 10.1016/j.gyobfe.2016.05.003. Epub 2016 Jun 27.
    • [Article in French]
    • A new strategy for prophylactic surgery in BRCA women: Combined mastectomy and laparoscopic salpingo-oophorectomy with immediate reconstruction by double DIEP flap.
    • Hunsinger V, Marchac AC, Derder M, Hivelin M, Lecuru F, Bats AS, Lantieri L.
    • Ann Chir Plast Esthet. 2016 Jun;61(3):177-82. doi: 10.1016/j.anplas.2016.02.002. Epub 2016 Mar 2.
    • The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    • Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.
    • BMC Cancer. 2016 Jan 14;16(1):18. doi: 10.1186/s12885-015-2011-5.
    • 2016 Genetics Toolkit
    • Society of Gynecologic Oncology
    • Society of Gynecologic Oncology. 2016.

    News: New Toolkit Can Help Debunk Myths About Genetic Testing for Gynecologic Cancer. (Cure)

    • Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: A reappraisal.
    • Oliver Perez MR, Magriñá J, García AT, Jiménez Lopez JS.
    • Surg Oncol. 2015 Dec;24(4):335-44. doi: 10.1016/j.suronc.2015.09.008. Epub 2015 Oct 8.
    • Review
    • Discussion: The Next Big Things in the BRCA World.
    • [No author given].
    • My Gene Counsel. 2015 Nov 4.
    • Outcomes and Cost Analysis in High-Risk Patients Undergoing Simultaneous Free Flap Breast Reconstruction and Gynecologic Procedures.
    • Del Corral GA, Wes AM, Fischer JP, Serletti JM, Wu LC.
    • Ann Plast Surg. 2015 Nov;75(5):534-8. doi: 10.1097/SAP.0000000000000156.
    • Opportunistic salpingectomy for ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Kwon JS, Mitchell G.
    • Gynecol Oncol Res Pract. 2015 Sep 17;2:5. doi: 10.1186/s40661-015-0014-1. eCollection 2015.
    • Laparoscopic Salpingo-oophorectomy in Conscious Sedation.
    • Rosati M, Bramante S, Conti F, Rizzi M, Frattari A, Spina T.
    • JSLS. 2015 Jul-Sep;19(3). pii: e2015.00031. doi: 10.4293/JSLS.2015.00031.
    • Public perception of risk-reducing salpingectomy for preventing ovarian cancer.
    • Kang JH, Nam SH, Song T, Kim WY, Lee KW, Kim KH.
    • Obstet Gynecol Sci. 2015 Jul;58(4):284-8. doi: 10.5468/ogs.2015.58.4.284. Epub 2015 Jul 16.
    • Single-port versus conventional multiport access prophylactic laparoscopic bilateral salpingo-oophorectomy in high-risk patients for ovarian cancer: a comparison of surgical outcomes.
    • Angioni S, Pontis A, Sedda F, Zampetoglou T, Cela V, Mereu L, Litta P.
    • Onco Targets Ther. 2015 Jun 25;8:1575-80. doi: 10.2147/OTT.S82570. eCollection 2015.
    • Oophorectomy benefits in breast cancer patients with BRCA1 mutation.
    • Brown S.
    • Post Reprod Health. 2015 Jun;21(2):46-7.
    • Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies.
    • Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J.
    • Genes Chromosomes Cancer. 2015 May;54(5):276-87. doi: 10.1002/gcc.22241. Epub 2015 Feb 23.
    • Clinical management of patients at inherited risk for gynecologic cancer.
    • Powell CB.
    • Curr Opin Obstet Gynecol. 2015 Feb;27(1):14-22. doi: 10.1097/GCO.0000000000000143.
    • Review
    • Committee opinion no. 620: salpingectomy for ovarian cancer prevention.
    • [No authors listed]
    • Obstet Gynecol. 2015 Jan;125(1):279-81. doi: 10.1097/01.AOG.0000459871.88564.09.
    • Bilateral salpingo-oophorectomy and adhesiolysis with single port access laparoscopy and use of diode laser in a BRCA carrier.
    • Angioni S, Pontis A, Sorrentino F, Nappi L.
    • Eur J Gynaecol Oncol. 2015;36(4):479-81.
    • Case Report
    • Pros and Cons of Hysterectomy at the Time of Risk-reducing Removal of Ovaries and Fallopian Tubes.
    • Jessica McAlpine.
    • FORCE. Be Empowered Webinars. 2014 Dec 17.
    • Is Salpingectomy ‘The Answer’ for BRCA Carriers?
    • Ellen T- Matloff.
    • My Gene Counsel. 2014 Dec 1.
    • [The importance of screening in oncogynecology].
    • Frühauf F, Sláma J, Zikán M.
    • Ceska Gynekol. 2014 Dec;79(6):491-8.
    • Review, [Article in Czech]
    • Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.
    • Ohman AW, Hasan N, Dinulescu DM.
    • Front Oncol. 2014 Nov 18;4:322. doi: 10.3389/fonc.2014.00322. eCollection 2014.
    • RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    • Blanco A, Gutiérrez-Enríquez S, Santamariña M, Montalban G, Bonache S, Balmaña J, Carracedo A, Diez O, Vega A.
    • Breast Cancer Res Treat. 2014 Aug;147(1):133-43. doi: 10.1007/s10549-014-3078-4. Epub 2014 Aug 3.
    • Prophylactic mastectomy with immediate reconstruction combined with simultaneous laparoscopic salpingo-oophorectomy via a transmammary route: a novel surgical approach to female BRCA-mutation carriers.
    • Perabò M, Fink V, Günthner-Biller M, von Bodungen V, Friese K, Dian D.
    • Arch Gynecol Obstet. 2014 Jun;289(6):1325-30. doi: 10.1007/s00404-013-3133-0. Epub 2014 Jan 4.
    • First case of prophylactic salpingectomy with single port access laparoscopy and a new diode laser in a woman with BRCA mutation.
    • Angioni S, Mais V, Pontis A, Peiretti M, Nappi L.
    • Gynecol Oncol Case Rep. 2014 May 19;9:21-3. doi: 10.1016/j.gynor.2014.05.002. eCollection 2014.
    • Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention.
    • McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, Gilks CB, Finlayson SJ, Huntsman DG, Miller DM; Ovarian Cancer Research Program of British Columbia.
    • Am J Obstet Gynecol. 2014 May;210(5):471.e1-471.e11. doi: 10.1016/j.ajog.2014.01.003. Epub 2014 Jan 9.

    Editorial, Comment:

    Salpingectomy, why not?

    • Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk.
    • Anton A, Schott S, Kaip G, Rath M, Heil J, Aulmann S, Sinn HP.
    • Arch Gynecol Obstet. 2014 May;289(5):1079-85. doi: 10.1007/s00404-013-3062-y. Epub 2013 Nov 7.
    • Prophylactic Surgery Recommended for BRCA1 Carriers.
    • [No authors listed]
    • Cancer Discov. 2014 May;4(5):OF1. doi: 10.1158/2159-8290.CD-NB2014-042. Epub 2014 Mar 27.
    • Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    • Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.
    • Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.
    • It Is Safe to Perform Gynecologic Surgery First in Patients Undergoing Combined Breast and Gynecologic Surgery.
    • Jack Basil, Rachel Sinkey, ; James C. Pavelka, J. Michael Guenther.
    • Obstetrics & Gynecology. 123(Suppl 1):182S, May 2014. doi: 10.1097/01.AOG.0000447201.43420.a0.
    • Conference abstract
    • Pure natural orifice transluminal endoscopic surgery (NOTES) involving peroral endoscopic salpingo-oophorectomy (POESY).
    • Hornemann A, Suetterlin M, Trunk MJ, Gerhardt A, Kaehler G.
    • Int J Gynaecol Obstet. 2014 Apr;125(1):86-8. doi: 10.1016/j.ijgo.2013.08.024. Epub 2014 Jan 2.
    • Case report
    • Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway.
    • Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, Li WY, Cescon DW, Li YT, Molyneux S, Penrod N, Lupien M, Schmidt EE, Stambolic V, Gauthier ML, Mak TW.
    • Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4472-7. doi: 10.1073/pnas.1324136111. Epub 2014 Feb 24.

    Comment:

    Tissue-specific tumor suppression by BRCA1.

    • Prophylactic Bilateral Salpingectomy as a Prevention Strategy in Women at High-Risk of Ovarian Cancer: A Mini-Review.
    • Schenberg T, Mitchell G.
    • Front Oncol. 2014 Feb 10;4:21. eCollection 2014.
    • Revisiting the pathogenesis of ovarian cancer: the central role of the fallopian tube.
    • Dietl J.
    • Arch Gynecol Obstet. 2014 Feb;289(2):241-6. doi: 10.1007/s00404-013-3041-3. Epub 2013 Oct 8.
    • Review
    • The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
    • Reade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2014 Feb;36(2):133-40.
    • Alternatives to risk-reducing surgery for ovarian cancer.
    • Gadducci A, Sergiampietri C, Tana R.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii47-viii53. doi: 10.1093/annonc/mdt311.
    • Increased Proliferative Background in Healthy Women with BRCA1/2 Haploinsufficiency Is Associated with High Risk for Breast Cancer.
    • Nisman B, Kadouri L, Allweis T, Maly B, Hamburger T, Gronowitz S, Peretz T.
    • Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5. doi: 10.1158/1055-9965.EPI-13-0193. Epub 2013 Aug 21.
    • Risk-reducing salpingectomy as a new and safe strategy to prevent ovarian cancer.
    • Morelli M, Venturella R, Zullo F.
    • Am J Obstet Gynecol. 2013 Oct;209(4):395-6. doi: 10.1016/j.ajog.2013.05.015. Epub 2013 May 9.

    Review:

    The role of the fallopian tube in the origin of ovarian cancer.

    Letter, Comment:

    Reply: To PMID 23583217.

    • The expression of BRCA1, P53, KAI1, and Nm23 in ovaries of BRCA1 mutation carriers after prophylactic adnexectomy.
    • Markowska J, Bar J, Mądry R, Słomska I, Mardas M, Grabowski JP.
    • Arch Gynecol Obstet. 2013 Oct;288(4):839-44. doi: 10.1007/s00404-013-2825-9. Epub 2013 Apr 4.
    • Challenging and complex decisions in the management of the BRCA mutation carrier.
    • Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.
    • J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29.
    • Opportunistic and interventional salpingectomy in women at risk: a strategy for preventing pelvic serous cancer (PSC).
    • Kamran MW, Vaughan D, Crosby D, Wahab NA, Saadeh FA, Gleeson N.
    • Eur J Obstet Gynecol Reprod Biol. 2013 Aug;170(1):251-4. doi: 10.1016/j.ejogrb.2013.06.030. Epub 2013 Jul 21.
    • Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists.
    • Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE.
    • J Obstet Gynaecol Can. 2013 Jul;35(7):627-34.
    • Mixed reviews on removing fallopian tubes to prevent ovarian cancer.
    • Kramer L.
    • CMAJ. 2013 Jun 11;185(9):E391-2. doi: 10.1503/cmaj.109-4475. Epub 2013 May 6.
    • Salpingectomy to prevent ovarian cancer: A Countercurrents Series.
    • Narod SA.
    • Curr Oncol. 2013 Jun;20(3):145-7. doi: 10.3747/co.20.1471.
    • Understanding the Needs of Women Considering Risk-Reducing Salpingo-oophorectomy.
    • Cherry C, Ropka M, Lyle J, Napolitano L, Daly MB.
    • Cancer Nurs. 2013 May-Jun;36(3):E33-8. doi: 10.1097/NCC.0b013e3182642cb5.
    • Experience of Risk-reducing Salpingo-oophorectomy for a BRCA1 Mutation Carrier and Establishment of a System Performing a Preventive Surgery for Hereditary Breast and Ovarian Cancer Syndrome in Japan: Our Challenges for the Future.
    • Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D.
    • Jpn J Clin Oncol. 2013 May;43(5):515-9. doi: 10.1093/jjco/hyt036. Epub 2013 Mar 13.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Surgical implications of the potential new tubal pathway for ovarian carcinogenesis.
    • Chene G, Rahimi K, Mes-Masson AM, Provencher D.
    • J Minim Invasive Gynecol. 2013 Mar-Apr;20(2):153-9. doi: 10.1016/j.jmig.2012.11.010. Epub 2013 Jan 16.
    • Review
    • Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    • Meiser B, Price MA, Butow PN, Karatas J, Wilson J, Heiniger L, Baylock B, Charles M, McLachlan SA, Phillips KA.
    • Fam Cancer. 2013 Mar;12(1):101-9. doi: 10.1007/s10689-012-9585-8.
    • Gynaecological cancer: Risk reduction surgery in non-BRCA carriers–is less more?
    • [No author given]
    • Nature Reviews Clinical Oncology. doi:10.1038/nrclinonc.2012.243. 2013 Feb.
    • High-Grade Serous Tumor Arising from Fallopian Tube in a BRCA Mutation Carrier after Prophylactic Oophorectomy.
    • Lorusso D, Di Rocco R, Mancini M, Raspagliesi F.
    • Case Rep Oncol. 2013 Jan;6(1):21-4. doi: 10.1159/000346339. Epub 2013 Jan 9.
    • The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?
    • Haldar K, Crawford R.
    • Gynecol Oncol. 2013 Jan;128(1):148-9. doi: 10.1016/j.ygyno.2012.08.019. Epub 2012 Aug 20.
    • Comment, Letter

    Editorial:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

    Letter, Reply:

    There is a need for routine peritoneal cytology at RRSO.

    • There is a need for routine peritoneal cytology at RRSO.
    • Manchanda R, Drapkin R, Menon U.
    • Gynecol Oncol. 2013 Jan;128(1):149-50. doi: 10.1016/j.ygyno.2012.09.031. Epub 2012 Oct 9.
    • Comment, Letter

    Letter, Comment:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?

    Editorial:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

    • Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers.
    • Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.
    • Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

    Editorial/Comment:

    Ideal Risk Reduction Management for Women With BRCA Gene Mutations: Still Not There Yet.

    • [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    • Bit-Sava EM, Belogurova MB, Imianitov EN, Balandov SG, Korniushin OV, Borisov MK.
    • Vopr Onkol. 2013;59(2):5-11.
    • Review, [Article in Russian]
    • Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation "previvors".
    • Holman L, Brandt A, Daniels M, Arun B, Keeler E, Gershenson D, Sun C, Lu K.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.048.
    • New findings presented on metastatic breast cancer and bilateral oophorectomy.
    • Printz C.
    • Cancer. 2012 Jun 1;118(11):2778. doi: 10.1002/cncr.27643.
    • Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older.
    • McCarthy AM, Menke A, Ouyang P, Visvanathan K.
    • Cancer Prev Res (Phila). 2012 Jun;5(6):847-54. doi: 10.1158/1940-6207.CAPR-11-0430. Epub 2012 May 3.
    • The potential for risk stratification in the management of ovarian cancer risk.
    • Pharoah PD.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S16-7. doi: 10.1097/IGC.0b013e318251caaf.
    • Review
    • Screening for gynaecologic cancers in genetically predisposed women.
    • Dreyer G.
    • Best Pract Res Clin Obstet Gynaecol. 2012 Apr;26(2):267-82. doi: 10.1016/j.bpobgyn.2011.11.002. Epub 2012 Feb 22.
    • Review
    • Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy.
    • Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM.
    • Fam Cancer. 2012 Mar;11(1):69-75. doi: 10.1007/s10689-011-9480-8.
    • Physician data query (PDQ®) update.
    • [No authors listed]
    • J Natl Cancer Inst. 2012 Feb 8;104(3):176. doi: 10.1093/jnci/djs025. Epub 2012 Jan 23.
    • The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.
    • Manchanda R, Drapkin R, Jacobs I, Menon U.
    • Gynecol Oncol. 2012 Feb;124(2):185-91. doi: 10.1016/j.ygyno.2011.10.017. Epub 2011 Oct 20.
    • Commentary

    Comment, Letter:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?

    Comment, Letter:

    There is a need for routine peritoneal cytology at RRSO.